<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:03:50Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10649338" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10649338</identifier>
        <datestamp>2023-10-28</datestamp>
        <setSpec>nutrients</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Nutrients</journal-id>
              <journal-id journal-id-type="iso-abbrev">Nutrients</journal-id>
              <journal-id journal-id-type="publisher-id">nutrients</journal-id>
              <journal-title-group>
                <journal-title>Nutrients</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2072-6643</issn>
              <publisher>
                <publisher-name>MDPI</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10649338</article-id>
              <article-id pub-id-type="pmcid">PMC10649338</article-id>
              <article-id pub-id-type="pmc-uid">10649338</article-id>
              <article-id pub-id-type="pmid">37960239</article-id>
              <article-id pub-id-type="pmid">37960239</article-id>
              <article-id pub-id-type="doi">10.3390/nu15214586</article-id>
              <article-id pub-id-type="publisher-id">nutrients-15-04586</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Neuroimaging Insights: Kava’s (<italic toggle="yes">Piper methysticum</italic>) Effect on Dorsal Anterior Cingulate Cortex GABA in Generalized Anxiety Disorder</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8075-9222</contrib-id>
                  <name>
                    <surname>Savage</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <xref rid="af1-nutrients-15-04586" ref-type="aff">1</xref>
                  <xref rid="af2-nutrients-15-04586" ref-type="aff">2</xref>
                  <xref rid="c1-nutrients-15-04586" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sarris</surname>
                    <given-names>Jerome</given-names>
                  </name>
                  <xref rid="af2-nutrients-15-04586" ref-type="aff">2</xref>
                  <xref rid="af3-nutrients-15-04586" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hughes</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <xref rid="af4-nutrients-15-04586" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6303-8696</contrib-id>
                  <name>
                    <surname>Bousman</surname>
                    <given-names>Chad A.</given-names>
                  </name>
                  <xref rid="af5-nutrients-15-04586" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rossell</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <xref rid="af4-nutrients-15-04586" ref-type="aff">4</xref>
                  <xref rid="af6-nutrients-15-04586" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4484-5462</contrib-id>
                  <name>
                    <surname>Scholey</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <xref rid="af1-nutrients-15-04586" ref-type="aff">1</xref>
                  <xref rid="af7-nutrients-15-04586" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3628-3220</contrib-id>
                  <name>
                    <surname>Stough</surname>
                    <given-names>Con</given-names>
                  </name>
                  <xref rid="af1-nutrients-15-04586" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Suo</surname>
                    <given-names>Chao</given-names>
                  </name>
                  <xref rid="af8-nutrients-15-04586" ref-type="aff">8</xref>
                </contrib>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Dakanalis</surname>
                    <given-names>Antonios</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <aff id="af1-nutrients-15-04586"><label>1</label>Centre for Human Psychopharmacology, Swinburne University of Technology, 427-451 Burwood Road, Melbourne 3122, Australia</aff>
              <aff id="af2-nutrients-15-04586"><label>2</label>Florey Institute of Neuroscience and Mental Health, Melbourne University, Melbourne 3121, Australia</aff>
              <aff id="af3-nutrients-15-04586"><label>3</label>NICM Health Research Institute, Western Sydney University, Sydney 2751, Australia</aff>
              <aff id="af4-nutrients-15-04586"><label>4</label>Centre for Mental Health, Swinburne University of Technology, Melbourne 3122, Australia</aff>
              <aff id="af5-nutrients-15-04586"><label>5</label>Departments of Medical Genetics, Psychiatry, Physiology &amp; Pharmacology, and Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada</aff>
              <aff id="af6-nutrients-15-04586"><label>6</label>Mental Health, St Vincent’s Hospital Melbourne, Melbourne 3065, Australia</aff>
              <aff id="af7-nutrients-15-04586"><label>7</label>Department of Nutrition, Dietetics and Food, Monash University, Melbourne 3168, Australia</aff>
              <aff id="af8-nutrients-15-04586"><label>8</label>Brain Park, Turner Institute of Brain and Mind, Monash University, Melbourne 3800, Australia</aff>
              <author-notes>
                <corresp id="c1-nutrients-15-04586"><label>*</label>Correspondence: <email>ksavage@swin.edu.au</email>; Tel.: +614-9214-9267</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>28</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>11</month>
                <year>2023</year>
              </pub-date>
              <volume>15</volume>
              <issue>21</issue>
              <elocation-id>4586</elocation-id>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
                <date date-type="rev-recd">
                  <day>07</day>
                  <month>10</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>25</day>
                  <month>10</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 by the authors.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <p>Generalised Anxiety Disorder (GAD) is a prevalent, chronic mental health disorder. The measurement of regional brain gamma-aminobutyric acid (GABA) offers insight into its role in anxiety and is a potential biomarker for treatment response. Research literature suggests <italic toggle="yes">Piper methysticum</italic> (Kava) is efficacious as an anxiety treatment, but no study has assessed its effects on central GABA levels. This study investigated dorsal anterior cingulate (dACC) GABA levels in 37 adult participants with GAD. GABA was measured using proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) at baseline and following an eight-week administration of Kava (standardised to 120 mg kavalactones twice daily) (<italic toggle="yes">n</italic> = 20) or placebo (<italic toggle="yes">n</italic> = 17). This study was part of the Kava for the Treatment of GAD (KGAD; ClinicalTrials.gov: NCT02219880), a 16-week intervention study. Compared with the placebo group, the Kava group had a significant reduction in dACC GABA (<italic toggle="yes">p</italic> = 0.049) at eight weeks. Baseline anxiety scores on the HAM-A were positively correlated with GABA levels but were not significantly related to treatment. Central GABA reductions following Kava treatment may signal an inhibitory effect, which, if considered efficacious, suggests that GABA levels are modulated by Kava, independent of reported anxiety symptoms. dACC GABA patterns suggest a functional role of higher levels in clinical anxiety but warrants further research for symptom benefit. Findings suggest that dACC GABA levels previously un-examined in GAD could serve as a biomarker for diagnosis and treatment response.</p>
              </abstract>
              <kwd-group>
                <kwd>anterior cingulate</kwd>
                <kwd>GABA</kwd>
                <kwd>generalised anxiety disorder</kwd>
                <kwd>kava</kwd>
                <kwd>magnetic resonance spectroscopy</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>Australian National Health and Medical Research Council (NHMRC)</funding-source>
                  <funding-source>Integria Healthcare</funding-source>
                  <award-id>APP1063383</award-id>
                </award-group>
                <award-group>
                  <funding-source>Australian Government Research Training Program (RTP) Stipend Scholarship</funding-source>
                </award-group>
                <award-group>
                  <funding-source>NHMRC Clinical Research Fellowship</funding-source>
                  <award-id>APP1125000</award-id>
                </award-group>
                <award-group>
                  <funding-source>Senior National Health and Medical Research Council (NHMRC) Fellowship</funding-source>
                  <award-id>GNT1154651</award-id>
                </award-group>
                <funding-statement>Data were derived from the larger KGAD clinical trial, funded by an Australian National Health and Medical Research Council (NHMRC) grant (No. APP1063383) and co-funded by Integria Healthcare. The Kava used as treatment in this study was sourced specifically for the trial and therefore represents a different product than the one currently marketed by Integria Healthcare. We acknowledge the facilities and technical assistance of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) capability, at the Swinburne Neuroimaging Facility, Swinburne University of Technology. KS was the recipient of an Australian Government Research Training Program (RTP) Stipend Scholarship. The aforementioned grant and sponsor funding sources also provided support for research included in this manuscript to obtain a PhD (KS). JS was supported by NHMRC Clinical Research Fellowship (APP1125000). SLR holds a Senior National Health and Medical Research Council (NHMRC) Fellowship (GNT1154651).</funding-statement>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1-nutrients-15-04586">
              <title>1. Introduction</title>
              <p>Generalised Anxiety Disorder (GAD) is a clinically challenging, prevalent, and chronic affective disorder associated with functional disablement, frequent comorbidities, and high psychological distress [<xref rid="B1-nutrients-15-04586" ref-type="bibr">1</xref>,<xref rid="B2-nutrients-15-04586" ref-type="bibr">2</xref>]. It is characterised by the two leading cognitive symptoms of persistent worry and anticipatory anxiety [<xref rid="B3-nutrients-15-04586" ref-type="bibr">3</xref>]. GAD prevalence and severity may be underreported, due in part to low diagnostic reliability [<xref rid="B4-nutrients-15-04586" ref-type="bibr">4</xref>,<xref rid="B5-nutrients-15-04586" ref-type="bibr">5</xref>,<xref rid="B6-nutrients-15-04586" ref-type="bibr">6</xref>,<xref rid="B7-nutrients-15-04586" ref-type="bibr">7</xref>]. Current stepped-care treatment for GAD typically involves antidepressant and benzodiazepine pharmacotherapies as well as cognitive behavioural therapy (CBT) [<xref rid="B8-nutrients-15-04586" ref-type="bibr">8</xref>,<xref rid="B9-nutrients-15-04586" ref-type="bibr">9</xref>,<xref rid="B10-nutrients-15-04586" ref-type="bibr">10</xref>]. These approaches, however, provide modest clinical effect and have limited utility for many patients [<xref rid="B11-nutrients-15-04586" ref-type="bibr">11</xref>,<xref rid="B12-nutrients-15-04586" ref-type="bibr">12</xref>,<xref rid="B13-nutrients-15-04586" ref-type="bibr">13</xref>,<xref rid="B14-nutrients-15-04586" ref-type="bibr">14</xref>,<xref rid="B15-nutrients-15-04586" ref-type="bibr">15</xref>,<xref rid="B16-nutrients-15-04586" ref-type="bibr">16</xref>]. Moreover, novel drug development has not progressed for two decades [<xref rid="B6-nutrients-15-04586" ref-type="bibr">6</xref>,<xref rid="B17-nutrients-15-04586" ref-type="bibr">17</xref>,<xref rid="B18-nutrients-15-04586" ref-type="bibr">18</xref>,<xref rid="B19-nutrients-15-04586" ref-type="bibr">19</xref>,<xref rid="B20-nutrients-15-04586" ref-type="bibr">20</xref>,<xref rid="B21-nutrients-15-04586" ref-type="bibr">21</xref>], leading many consumers to utilise anxiolytic phytomedicines [<xref rid="B22-nutrients-15-04586" ref-type="bibr">22</xref>,<xref rid="B23-nutrients-15-04586" ref-type="bibr">23</xref>].</p>
              <p>GAD remains the most understudied of the anxiety disorders [<xref rid="B6-nutrients-15-04586" ref-type="bibr">6</xref>,<xref rid="B24-nutrients-15-04586" ref-type="bibr">24</xref>]. One promising avenue to advance GAD diagnosis and the assessment of treatment efficacy is to investigate the neuroimaging biomarkers [<xref rid="B25-nutrients-15-04586" ref-type="bibr">25</xref>,<xref rid="B26-nutrients-15-04586" ref-type="bibr">26</xref>,<xref rid="B27-nutrients-15-04586" ref-type="bibr">27</xref>,<xref rid="B28-nutrients-15-04586" ref-type="bibr">28</xref>] that may offer insight into the mechanisms of anxiety; however, the extent to which brain metabolic processes are instrumental in pathology remains unclear.</p>
              <sec id="sec1dot1-nutrients-15-04586">
                <title>1.1. Gamma-Aminobutyric Acid (GABA) and Quantification in the CNS</title>
                <p>GABA (C4H9NO2C4) is a non-standard amino acid that acts as the major inhibitory neurotransmitter [<xref rid="B29-nutrients-15-04586" ref-type="bibr">29</xref>,<xref rid="B30-nutrients-15-04586" ref-type="bibr">30</xref>]. GABA is distributed throughout the brain but is highly concentrated in cortical and limbic areas associated with ‘anxiety circuitry’ [<xref rid="B31-nutrients-15-04586" ref-type="bibr">31</xref>,<xref rid="B32-nutrients-15-04586" ref-type="bibr">32</xref>]. In these regions, multi-modal neuroimaging studies demonstrate a trend of emotion task-dependent stronger negative BOLD signal observed with a higher resting state GABA [<xref rid="B33-nutrients-15-04586" ref-type="bibr">33</xref>,<xref rid="B34-nutrients-15-04586" ref-type="bibr">34</xref>,<xref rid="B35-nutrients-15-04586" ref-type="bibr">35</xref>].</p>
                <p>In pre-clinical rodent models, high anxiety-behaviour mice exhibit higher levels of amygdala GABA and a greater expression of GABA pathway components GAD65 and GAD67 than normal anxiety-behaviour mice [<xref rid="B36-nutrients-15-04586" ref-type="bibr">36</xref>]. Clinical studies place GABA in a central role in neuropathology across anxiety states and disorders [<xref rid="B15-nutrients-15-04586" ref-type="bibr">15</xref>,<xref rid="B32-nutrients-15-04586" ref-type="bibr">32</xref>,<xref rid="B34-nutrients-15-04586" ref-type="bibr">34</xref>,<xref rid="B37-nutrients-15-04586" ref-type="bibr">37</xref>,<xref rid="B38-nutrients-15-04586" ref-type="bibr">38</xref>,<xref rid="B39-nutrients-15-04586" ref-type="bibr">39</xref>], whereby elevated GABA is associated with anxiety cognitions in healthy samples in the ventral-medial prefrontal cortex (vmPFC) [<xref rid="B40-nutrients-15-04586" ref-type="bibr">40</xref>] and the medial pre-frontal cortex in post-traumatic stress disorder (PTSD) [<xref rid="B41-nutrients-15-04586" ref-type="bibr">41</xref>]. However, in PTSD, GABA levels are <italic toggle="yes">reduced</italic> compared to controls in the lateral temporal lobe, ACC, insula, and parieto-occipital cortices, but no differences are observed in the dACC region [<xref rid="B42-nutrients-15-04586" ref-type="bibr">42</xref>,<xref rid="B43-nutrients-15-04586" ref-type="bibr">43</xref>]. In panic disorder, GABA is reduced in the occipital and ACC regions and the basal ganglia [<xref rid="B44-nutrients-15-04586" ref-type="bibr">44</xref>,<xref rid="B45-nutrients-15-04586" ref-type="bibr">45</xref>], but it is not different in the pre-frontal cortex [<xref rid="B46-nutrients-15-04586" ref-type="bibr">46</xref>]. Social Anxiety Disorder (SAD) research suggests reduced thalamic GABA levels but no other regional differences compared with controls [<xref rid="B47-nutrients-15-04586" ref-type="bibr">47</xref>]. Taken together, the evidence suggests that GABA varies by region and disorder, but no research has yet directly assessed regional levels in GAD adults compared with healthy controls. In GAD intervention research, other metabolites such as n-acetyl aspartate following riluzole or paroxetine administration [<xref rid="B48-nutrients-15-04586" ref-type="bibr">48</xref>,<xref rid="B49-nutrients-15-04586" ref-type="bibr">49</xref>,<xref rid="B50-nutrients-15-04586" ref-type="bibr">50</xref>] have been investigated, but no study has thus far assessed GABA levels as a product of anxiolytic treatment.</p>
              </sec>
              <sec id="sec1dot2-nutrients-15-04586">
                <title>1.2. The Dorsal Anterior Cingulate Cortex (dACC) as a Region of Interest</title>
                <p>The ACC has a central role in the organisation of affective and cognitive information that underpin anxiety states via its connectivity to prefrontal-cortical, lower limbic, and hippocampal regions [<xref rid="B51-nutrients-15-04586" ref-type="bibr">51</xref>,<xref rid="B52-nutrients-15-04586" ref-type="bibr">52</xref>,<xref rid="B53-nutrients-15-04586" ref-type="bibr">53</xref>,<xref rid="B54-nutrients-15-04586" ref-type="bibr">54</xref>,<xref rid="B55-nutrients-15-04586" ref-type="bibr">55</xref>]. Sub-regions of the ACC are implicated in GAD symptomatology—notably, anticipatory anxiety and negative bias cognitions [<xref rid="B56-nutrients-15-04586" ref-type="bibr">56</xref>,<xref rid="B57-nutrients-15-04586" ref-type="bibr">57</xref>,<xref rid="B58-nutrients-15-04586" ref-type="bibr">58</xref>,<xref rid="B59-nutrients-15-04586" ref-type="bibr">59</xref>]. Structural and functional studies support a rostral/affective and a dorsal/cognitive division of ACC sub-regions, with a heterogeneous and integrative role of the latter in the cognitive components of emotional processing [<xref rid="B51-nutrients-15-04586" ref-type="bibr">51</xref>,<xref rid="B53-nutrients-15-04586" ref-type="bibr">53</xref>,<xref rid="B60-nutrients-15-04586" ref-type="bibr">60</xref>,<xref rid="B61-nutrients-15-04586" ref-type="bibr">61</xref>,<xref rid="B62-nutrients-15-04586" ref-type="bibr">62</xref>].</p>
                <p>This dorsal region comprises a fear network along with the ventromedial prefrontal cortex and amygdala [<xref rid="B63-nutrients-15-04586" ref-type="bibr">63</xref>,<xref rid="B64-nutrients-15-04586" ref-type="bibr">64</xref>], with GABA levels in this region contributing to the maintenance of anxiety cognition–emotion fear responses and reducing fear extinction [<xref rid="B61-nutrients-15-04586" ref-type="bibr">61</xref>,<xref rid="B62-nutrients-15-04586" ref-type="bibr">62</xref>], suggesting that the cognitive control of worry thoughts is a hallmark of GAD. Yet, despite the evidence that ACC sub-regions are a significant predictor in intervention studies—at least in structural and functional studies [<xref rid="B26-nutrients-15-04586" ref-type="bibr">26</xref>,<xref rid="B64-nutrients-15-04586" ref-type="bibr">64</xref>]—it has received little focus in terms of metabolic data quantification to establish patterns in GAD symptomology, and for these reasons, the dACC is of particular interest in this investigation.</p>
              </sec>
              <sec id="sec1dot3-nutrients-15-04586">
                <title>1.3. Kava for the Treatment of GAD Symptoms</title>
                <p>The phytomedicine <italic toggle="yes">Piper methysticum</italic> (Kava) holds a compelling evidence base for the alleviation of anxiety symptoms [<xref rid="B65-nutrients-15-04586" ref-type="bibr">65</xref>,<xref rid="B66-nutrients-15-04586" ref-type="bibr">66</xref>,<xref rid="B67-nutrients-15-04586" ref-type="bibr">67</xref>,<xref rid="B68-nutrients-15-04586" ref-type="bibr">68</xref>], and it is a popular consumer treatment with over 1.2 million Kava extract tablets prescribed or purchased annually in Australia [<xref rid="B69-nutrients-15-04586" ref-type="bibr">69</xref>]. The water extraction method is the only allowable process in Australia, and tableted Kava products are typically standardised to 30% kavalactones, constituting quantities of 80 to 250 mg.</p>
                <p>The Kava plant is a perennial shrub of the pepper family <italic toggle="yes">Piperaceae</italic>, and it is native to the South Pacific, where the rootstock lipid resin has been used for millennia in traditional medicine for its anxiolytic, nootropic, neuroprotective, nociceptive, and anti-dysphoria effects [<xref rid="B70-nutrients-15-04586" ref-type="bibr">70</xref>,<xref rid="B71-nutrients-15-04586" ref-type="bibr">71</xref>,<xref rid="B72-nutrients-15-04586" ref-type="bibr">72</xref>,<xref rid="B73-nutrients-15-04586" ref-type="bibr">73</xref>]. The chief bioactive constituents are kavalactones, six of which comprise the majority of Kava’s pharmacodynamic effects: dihydrokavain/dihydrokawain, kavain/kawain, dihydromethysticin, methysticin, yangonin, and demethoxyyangonin, in order of typical proportion [<xref rid="B74-nutrients-15-04586" ref-type="bibr">74</xref>,<xref rid="B75-nutrients-15-04586" ref-type="bibr">75</xref>,<xref rid="B76-nutrients-15-04586" ref-type="bibr">76</xref>,<xref rid="B77-nutrients-15-04586" ref-type="bibr">77</xref>].</p>
                <p>The proposed mechanism of the <italic toggle="yes">GABAergic</italic> effect occurs through the positive modulation of multiple benzodiazepine binding sites, including GABA-A and GABA-B from kavain, yangonin, dehydromethysticin, and desmethoxyyangonin, through both enhanced ligand displacement and binding [<xref rid="B75-nutrients-15-04586" ref-type="bibr">75</xref>,<xref rid="B78-nutrients-15-04586" ref-type="bibr">78</xref>,<xref rid="B79-nutrients-15-04586" ref-type="bibr">79</xref>,<xref rid="B80-nutrients-15-04586" ref-type="bibr">80</xref>]. Pre-clinical studies also suggest mechanisms occurring within the GABA metabolic shunt, such as the modulation of the calcium ion channel blockade of the monoamine oxidase-B receptor substrate, thereby inhibiting glutamate and promoting GABA synthesis [<xref rid="B70-nutrients-15-04586" ref-type="bibr">70</xref>,<xref rid="B81-nutrients-15-04586" ref-type="bibr">81</xref>,<xref rid="B82-nutrients-15-04586" ref-type="bibr">82</xref>,<xref rid="B83-nutrients-15-04586" ref-type="bibr">83</xref>].</p>
                <p>Previous Kava investigations in anxiety report significant improvements on anxiety scales, such as the HAM-A [<xref rid="B22-nutrients-15-04586" ref-type="bibr">22</xref>,<xref rid="B84-nutrients-15-04586" ref-type="bibr">84</xref>,<xref rid="B85-nutrients-15-04586" ref-type="bibr">85</xref>]. However, only one study has investigated the modulation of brain markers. In an electroencephalography (EEG) resting state study [<xref rid="B86-nutrients-15-04586" ref-type="bibr">86</xref>], acute doses of kavain (200, 400, 600 mg), placebo, and 30 mg of clobazam were administered to a healthy sample (<italic toggle="yes">n</italic> = 15). Significant dose-dependent increases were observed in frontal lobe delta, theta, and alpha 1 activity in the frontal lobe and, together with improvements to mood and wellbeing measures, were reported in the kavain group. The psychotropic effects and topographic pattern differed from the benzodiazepine, particularly with 200 mg, where benefits to mood measures were reported, but sedation was reported at higher doses. The data are consistent with pre-clinical models on kavain as a positive allosteric modulator of the GABA-A receptor outside the typical benzodiazepine site binding [<xref rid="B75-nutrients-15-04586" ref-type="bibr">75</xref>]. Data from this study contribute to the evidence of unique GABAergic action with kavalactones, supported by pre-clinical tissue studies. This single study also highlights the need to examine Kava effects via other neuroimaging modalities to better understand its neurobiological mechanisms.</p>
                <p>To this end, this study aimed to investigate changes to GABA levels in the dorsal ACC in a GAD sample following the daily ingestion of Kava extract for eight weeks in comparison with a placebo group. This study also aimed to assess the relationship between GABA levels and changes to reported anxiety symptoms as a product of Kava consumption over the same period. It was expected that dACC GABA levels would decrease after Kava treatment and a reduction to anxiety symptoms would also be observed in comparison with the placebo group.</p>
              </sec>
            </sec>
            <sec sec-type="methods" id="sec2-nutrients-15-04586">
              <title>2. Methods and Materials</title>
              <sec id="sec2dot1-nutrients-15-04586">
                <title>2.1. Design</title>
                <p>This neuroimaging sub-study was conducted as part of the Kava for the Treatment of Generalised Anxiety Disorder clinical trial (KGAD) [<xref rid="B87-nutrients-15-04586" ref-type="bibr">87</xref>], a double-blinded, placebo-controlled investigation of 16-week’s administration of Kava in individuals with GAD. The sub-study’s eight-week duration was selected based on kava pharmacodynamics in both pre-clinical and clinical efficacy studies. The KGAD trial was registered via ClinicalTrials.gov (NCT02219880), with approval from the University of Melbourne/Alfred Hospital, the University of Queensland, and Swinburne University’s Human Research Ethics Committee. The clinical trial was conducted in accordance with the Declaration of Helsinki.</p>
              </sec>
              <sec sec-type="subjects" id="sec2dot2-nutrients-15-04586">
                <title>2.2. Participants</title>
                <p>Participants involved in the neuroimaging component of the study were adults aged 18–65 years with Generalized Anxiety Disorder; <italic toggle="yes">n</italic> = 37 (male <italic toggle="yes">n</italic> = 18). Screening and eligibility criteria can be found in both the protocol and main outcome papers for the KGAD study [<xref rid="B87-nutrients-15-04586" ref-type="bibr">87</xref>,<xref rid="B88-nutrients-15-04586" ref-type="bibr">88</xref>] and are summarised in <xref rid="app1-nutrients-15-04586" ref-type="app">Appendix A</xref>. All enrolled participants received a bursary of $200 to cover expenses. Written and informed consent was collected from all participants before comprehensive screening for eligibility.</p>
              </sec>
              <sec id="sec2dot3-nutrients-15-04586">
                <title>2.3. Sample Size</title>
                <p>With an a priori population sample size of N = 40 (<italic toggle="yes">n</italic> = 20 per group), a 95% confidence interval, a 5% margin of error (for a standard alpha of 0.05), and a small-to-medium effect size (confidence interval reporting was the chosen parameter), a minimum total sample size of <italic toggle="yes">n</italic> = 37 was determined using the G.Power calculation program [<xref rid="B89-nutrients-15-04586" ref-type="bibr">89</xref>].</p>
              </sec>
              <sec id="sec2dot4-nutrients-15-04586">
                <title>2.4. Measures</title>
                <sec id="sec2dot4dot1-nutrients-15-04586">
                  <title>2.4.1. Screening and Eligibility</title>
                  <p>The Mini-International Neuropsychiatric Interview (MINI 6.0) [<xref rid="B90-nutrients-15-04586" ref-type="bibr">90</xref>] was used to confirm the presence of current GAD according to the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5) [<xref rid="B91-nutrients-15-04586" ref-type="bibr">91</xref>], as well as identify secondary anxiety disorders and major depressive disorder (MDD) and the exclusion of other disorders. To ensure current GAD, moderate levels of anxiety (minimum 18 score) were required for enrolment to the study, assessed via the Hamilton Anxiety Rating Scale (HAM-A) [<xref rid="B92-nutrients-15-04586" ref-type="bibr">92</xref>]. The Montgomery–Asberg Depression Rating Scale (MADRS) [<xref rid="B93-nutrients-15-04586" ref-type="bibr">93</xref>] was utilised at both time points in the GAD group to ensure that symptoms of depression were not primary upon enrolment nor emergent following treatment (maximum score 18). The Structured Interview Guide for the MADRS was administered using a standardised line of questioning to ensure reliability and consistency (SIGMA) [<xref rid="B94-nutrients-15-04586" ref-type="bibr">94</xref>].</p>
                </sec>
                <sec id="sec2dot4dot2-nutrients-15-04586">
                  <title>2.4.2. Assessment of Comorbidity in GAD</title>
                  <p>Comorbidity (anxiety disorder or major depression) is not typically accounted for in neuroimaging studies with GAD samples. The prevalence of comorbidity in GAD is higher compared with other affective disorders, amplifying impairment [<xref rid="B95-nutrients-15-04586" ref-type="bibr">95</xref>,<xref rid="B96-nutrients-15-04586" ref-type="bibr">96</xref>]. Allowable secondary conditions were SAD, panic disorder with/without agoraphobia, and phobic disorder. MDD history was allowable if no episodes had occurred in the previous three years. This approach considers the likelihood of overlap in diagnoses in GAD where symptoms might be best explained by comorbidities such as MDD. Additional comorbid conditions may imply an increased severity of symptoms where higher anxiety measure scores may be observed. For this reason, a comorbid presence was either defined as a separate GAD group or used as a covariate in regression models.</p>
                </sec>
                <sec id="sec2dot4dot3-nutrients-15-04586">
                  <title>2.4.3. Assessment of Anxiety</title>
                  <p>The HAM-A is a 14-item 5-point Likert scale to quantify the severity of anxiety symptomatology. The Structured Interview version (SIGH-A) was used in this study to ensure a standardised questioning format in the assessment of anxiety levels at baseline and eight-week time points. The reliability and validity of the SIGH-A was assessed to be moderate to high [<xref rid="B97-nutrients-15-04586" ref-type="bibr">97</xref>].</p>
                </sec>
              </sec>
              <sec id="sec2dot5-nutrients-15-04586">
                <title>2.5. H-MRS Protocol</title>
                <p>A 3T Siemens TIM Trio magnetic resonance imaging system (Erlangen, Germany) with a 32-channel head coil housed at Swinburne Neuroimaging Centre (Hawthorn, Australia) was used for collecting <sup>1</sup>H-MRS and T1-weighted structural imaging data. T1-weighted images were acquired for the localisation of the MRS voxel at dorsal anterior cingulate cortex (high-resolution 1 mm<sup>3</sup>, 176 slices, voxel resolution = 1.0 × 1.0 × 7.0 mm<sup>3</sup>, TR = 1900 ms, TE = 2.52 ms, flip angle = 9°, field of view 256 × 256 mm, orientation sagittal, acquisition time = ~3 min).</p>
                <p>GABA quantification was conducted using Mescher–Garwood algorithm (MEGA) [<xref rid="B98-nutrients-15-04586" ref-type="bibr">98</xref>] in a Point RESolved Spectroscopy sequence (MEGA-PRESS), which is sensitive to GABA by editing the J-coupling between GABA-3 (peak at 3.01 ppm) and GABA-4 (peak at 1.89 ppm). The details of the sequences are as follows: TE = 68, TR = 2000, suppression freq. = 1.95 ppm, Ave = 64, ~5 min, editing pulse at 1.95 ppm (edit-on) interleaved with scans with a pulse at 7.5 ppm (edit-off). The water signal (unsuppressed signal) was acquired at the identical location with 16 averages for two minutes’ duration. Shimming was automatic and manual until the linewidth was less than 20 Hz for the 80/68 TE PRESS and MEGA-PRESS sequences.</p>
                <sec id="sec2dot5dot1-nutrients-15-04586">
                  <title>2.5.1. Voxel Placement and Check</title>
                  <p>The MRS voxel was 25 × 25 × 15 mm and covered the dACC. An in-house MATLAB (R2013b) script was applied to build a voxel image based on the location information on the head of MRS data. This voxel image indicates the location of the MRS voxel, when overlapping on the corresponding structural image at the same scan session. To check whether the location of the MRS voxel covered the target region, i.e., dACC at coordinates [0, 34, 26] in MNI (standard) space, individual structural images were co-registered to a MNI template, and the same transform matrix was applied on the corresponding voxel images. Finally, tissue segmentation was conducted at individual space to segment grey matter (GM), white matter (WM), and CSF. The volumetric proportion (percentage) of each tissue type within the MRS voxel was further calculated for partial volume correction and quality check (refer to <xref rid="nutrients-15-04586-f001" ref-type="fig">Figure 1</xref>). All individual voxel images were summarised and plotted on top of an MNI template using MRIcron [<xref rid="B99-nutrients-15-04586" ref-type="bibr">99</xref>], visible in <xref rid="nutrients-15-04586-f002" ref-type="fig">Figure 2</xref>, where the dACC was well covered.</p>
                </sec>
                <sec id="sec2dot5dot2-nutrients-15-04586">
                  <title>2.5.2. GABA Analysis</title>
                  <p>The difference spectrum (edit-on versus edit-off) was used to quantify the concentration of metabolites, including GABA. Fit checks were performed during preprocessing using GANNET, which utilises a peak fitting/integration method and applies a stricter model in its Fit Error quality control, aiding the removal of spurious cases [<xref rid="B100-nutrients-15-04586" ref-type="bibr">100</xref>]. Following vetting of the data against quality check parameters (SNR &gt; 5, SD &lt; 20%, FWHM &lt; 0.15), the voxel location was also visually inspected by overlapping the reconstructed voxel image and the T1-weighted MR image using in-house script and the MRIcron program. The LCModel toolbox (version 6.1) [<xref rid="B101-nutrients-15-04586" ref-type="bibr">101</xref>,<xref rid="B102-nutrients-15-04586" ref-type="bibr">102</xref>] is a widely used program for <sup>1</sup>H-MRS analyses, and a standard GABA basis set, matching the imaging protocol, was used for model fittings.</p>
                  <p>Partial volume correction (e.g., voxel segmentation) is a crucial component of the imaging pipeline when assessing voxel metabolite levels to prevent the inflation of quantification data that come from variances in grey and white matter [<xref rid="B103-nutrients-15-04586" ref-type="bibr">103</xref>,<xref rid="B104-nutrients-15-04586" ref-type="bibr">104</xref>,<xref rid="B105-nutrients-15-04586" ref-type="bibr">105</xref>,<xref rid="B106-nutrients-15-04586" ref-type="bibr">106</xref>]. As the concentration of GABA in grey matter is substantially higher than in white matter, further partial volume effects were corrected approximately by considering the grey matter volume ratio of the voxel of interest [<xref rid="B107-nutrients-15-04586" ref-type="bibr">107</xref>]. Briefly, tissue segmentation was conducted at a whole brain level by SPM12; then, the reconstructed MRS voxel (detailed in <xref rid="sec2dot5dot1-nutrients-15-04586" ref-type="sec">Section 2.5.1</xref>) were overlapped on tissue maps to determine the volume of grey matter, white matter, and CSF. The corrected GABA concentration was converted using the equation below, where GMV, WMV, and CSF represents the volume of grey matter, white matter, and CSF.
<disp-formula id="FD1-nutrients-15-04586"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:msub><mml:mo>÷</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">V</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">W</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">V</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">V</mml:mi></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mi mathvariant="normal">%</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                </sec>
              </sec>
              <sec id="sec2dot6-nutrients-15-04586">
                <title>2.6. Treatment Handling</title>
                <p>Procedures relating to treatment randomisation, the handling of treatment-related adverse events, and liver function assessment, as well as treatment compliance, are detailed in the KGAD study protocol and main outcome papers.</p>
              </sec>
              <sec id="sec2dot7-nutrients-15-04586">
                <title>2.7. Statistical Analyses</title>
                <p>Data were analysed using the IBM Statistical Package for Social Sciences software (SPSS; v.22, Armonk, NY, USA). All relevant demographic data were assessed at baseline treatment group differences via simple significance testing (<italic toggle="yes">t</italic>-tests and non-parametric tests were used when parametric criteria were not met), following quality checks for outliers and missing or incorrect data. Volumetric data, GABA QC variables, and GABA concentration results were reported separately by means and SDs for the variable of interest. It is feasible that age and sex-related differences would be observable in the samples tested in this study, potentially affecting results if not accounted for. For this reason, age and sex were employed in all group-based analyses to best delineate treatment group-based differences in function and GABA. An initial correlation test was performed to assess the relationship between GABA concentration levels and anxiety baseline data with covariates of sex, age, and comorbidity.</p>
                <p>Intervention analyses were performed using a custom main effects format for GABA outcomes, with the main outcome reported from the interaction of <italic toggle="yes">treatment x time</italic> on GABA concentration and a linear mixed model format for <italic toggle="yes">treatment x time x GABA</italic> significance on anxiety symptoms change. Confidence intervals were reported to establish parameter estimates, with a proportion of variance (reported in the text as a percent) for significant predictors. Statistical findings were considered significant if the probability value <italic toggle="yes">p</italic> ≤ 0.05.</p>
              </sec>
            </sec>
            <sec id="sec3-nutrients-15-04586">
              <title>3. Procedure</title>
              <p>Participants attended a screening session at the study site (Swinburne University of Technology, Melbourne) to assess study eligibility, followed by a baseline session, a supply of study treatment (240 mg daily tablets of kava or placebo), and a follow-up at eight weeks. Sociodemographic information included age in years, sex (male/female), BMI, medical conditions, alcohol consumption per week, allowable medication use (prophylactics), and eligible vitamins and supplements as determined by the protocol for the KGAD study [<xref rid="B87-nutrients-15-04586" ref-type="bibr">87</xref>]. Blood samples were collected at screening and follow up to assess liver function following overnight fasting, without alcohol or caffeine in the previous 24 h period. A standardised breakfast was provided followed by demographic data collection and psychiatric assessments. The scan was conducted in the same building one hour following arrival for the testing sessions. Processes, including the time of visit and scheduled scan, were replicated at the second time point (eight weeks).</p>
            </sec>
            <sec sec-type="results" id="sec4-nutrients-15-04586">
              <title>4. Results</title>
              <sec id="sec4dot1-nutrients-15-04586">
                <title>4.1. Description of the Study Population</title>
                <p>The <italic toggle="yes">CONSORT diagram</italic> in <xref rid="nutrients-15-04586-f003" ref-type="fig">Figure 3</xref> illustrates the study processes as well as participant numbers at screening, allocation, follow-up, and analysis. Demographic statistics overall and per treatment groups, including HAM-A scores and GABA data, are reported in <xref rid="nutrients-15-04586-t001" ref-type="table">Table 1</xref>. Treatment groups at baseline showed no significant differences in demographic data including age, sex, years of education, medication use, and caffeine or alcohol use. Baseline HAM-A scores for anxiety and the MADRS for depression symptoms were not significantly different between treatment groups (<italic toggle="yes">p</italic> = 0.714; <italic toggle="yes">p</italic> = 0.456, respectively).</p>
              </sec>
              <sec id="sec4dot2-nutrients-15-04586">
                <title>4.2. Adverse Events</title>
                <p>Adverse events reported during the study enrolment were not significantly different between participants in the kava and placebo groups (<italic toggle="yes">p</italic> = 0.508). The active treatment <italic toggle="yes">P. methysticum</italic> extract was well tolerated, with one participant reporting an adverse event of dizziness and a headache of mild severity with a probable association to kava. There were no serious adverse events reported in this study.</p>
              </sec>
              <sec id="sec4dot3-nutrients-15-04586">
                <title>4.3. Withdrawals</title>
                <p>The attrition of the sample size following the baseline visit was 46% (<italic toggle="yes">n</italic> = 17) and was not significantly different between the two groups (<italic toggle="yes">p</italic> = 0.482) for the following reasons and frequencies: non-compliance with study protocol (<italic toggle="yes">n</italic> = 6), lost to follow-up (<italic toggle="yes">n</italic> = 3), personal reasons/unspecified (<italic toggle="yes">n</italic> = 5), psychiatric status change (depression symptoms worsening, <italic toggle="yes">n</italic> = 2), medication status change (antidepressant course, <italic toggle="yes">n</italic> = 2), and pregnancy (<italic toggle="yes">n</italic> = 1).</p>
              </sec>
              <sec id="sec4dot4-nutrients-15-04586">
                <title>4.4. Structural Data and Metabolite Quantification</title>
                <p>The volumetric analysis showed no significant treatment group differences. The only quality parameter to display significant group differences was FWHM, <italic toggle="yes">t</italic>(37)2.29, <italic toggle="yes">p</italic> = 0.025, which was higher in the kava group (m 0.09, SD 0.05) than placebo (m 0.06, 0.02), meaning a better quality signal for the placebo group.</p>
                <sec id="sec4dot4dot1-nutrients-15-04586">
                  <title>4.4.1. GABA Concentration Levels and HAMA at Baseline</title>
                  <p>The <italic toggle="yes">t</italic>-test for the treatment group difference on anxiety levels via the HAMA at baseline was not significant (<italic toggle="yes">p</italic> = 0.932). Partial correlation revealed a significant moderate positive relationship between HAMA scores and GABA concentration level, <italic toggle="yes">r</italic>(24) = 0.40, <italic toggle="yes">p</italic> = 0.05.</p>
                </sec>
                <sec id="sec4dot4dot2-nutrients-15-04586">
                  <title>4.4.2. GABA Concentration Level Changes as a Function of the Eight-Week Kava Treatment</title>
                  <p>The partial volume-corrected GABA concentration in the grey matter model showed a significant treatment by time interaction, <italic toggle="yes">F</italic>(1, 21) = 4.36, <italic toggle="yes">p</italic> = 0.049. The model is shown in <xref rid="nutrients-15-04586-t002" ref-type="table">Table 2</xref>. Pairwise comparisons at the second time point indicated that the kava group was 1.06 units lower than the placebo group, and this was statistically significant (<italic toggle="yes">p</italic> = 0.008), 95% CI [−1.83, −0.28]. Refer to <xref rid="nutrients-15-04586-f004" ref-type="fig">Figure 4</xref>.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion" id="sec5-nutrients-15-04586">
              <title>5. Discussion</title>
              <p>The purpose of the study was to investigate GABA concentration in the dorsal ACC in adults with diagnosed GAD and to assess whether these levels were modified by Kava. A significant difference in GABA concentration was observed in the Kava group at eight weeks compared with the placebo group, showing a reduction in GABA concentration levels in the ROI.</p>
              <p>The study operated as a ‘proof of concept’ investigation, both in establishing the measurement of GABA in GAD and in evidencing neural mechanisms amenable to Kava. It addressed these aims through assessing GAD symptoms and biological outcomes before examining the role of Kava on both GABA levels and anxiety symptoms.</p>
              <p>This study found that baseline anxiety levels were positively associated with GABA levels in the dACC but that a daily dose of 240 mg <italic toggle="yes">P. methysticum</italic> extract for eight weeks was not successful in reducing anxiety symptomatology at the eight-week time point. The overarching clinical trial for which this study was conducted similarly found no anxiety improvements in the Kava group over the 16-week treatment period [<xref rid="B88-nutrients-15-04586" ref-type="bibr">88</xref>]. These findings contribute evidence for a lack of efficacy of the particular Kava extract in GAD, which is in contrast to earlier studies, reviews, and meta-analyses suggesting otherwise [<xref rid="B22-nutrients-15-04586" ref-type="bibr">22</xref>,<xref rid="B108-nutrients-15-04586" ref-type="bibr">108</xref>,<xref rid="B109-nutrients-15-04586" ref-type="bibr">109</xref>]. A caveat may be the small–moderate effect sizes in intervention efficacy studies [<xref rid="B10-nutrients-15-04586" ref-type="bibr">10</xref>], where many findings were also equivocal, supporting the observation in the literature that GAD is a clinically challenging disorder to treat.</p>
              <p>Despite these findings, results suggest that Kava modifies brain GABA levels, as GABA level reductions were observed in the Kava group in the dACC region compared with the placebo group. This reduction could represent a ‘normalisation’ in GABA levels, which is reflected in the handful of studies in the area that show that raised GABA is linked to anxiety levels in healthy samples, as well as elevations in PTSD compared with healthy controls [<xref rid="B41-nutrients-15-04586" ref-type="bibr">41</xref>,<xref rid="B42-nutrients-15-04586" ref-type="bibr">42</xref>]. Overall, the evidence is not sufficient to conclude trends in the dorsal ACC or within GAD groups.</p>
              <p>Given the bioactive constituent profile of the extract used in this study and the GABAergic mechanisms exerted by kavain, dihydrokavain, and methysticin in particular, it is feasible that the observed effects have occurred via enhancement to particular GABA-A receptor subtypes in the ROI through direct ligand-binding enhancement or indirectly via reductions to thromboxane A (2), which antagonises GABA-A receptor functions. It is also likely that modulations have occurred elsewhere in the shunt, such as the excitatory glutaminergic corollary through calcium ion channel blockades via the MAO-B receptor substrate, and there is increasing evidence of glutaminergic modulation in preclinical research [<xref rid="B110-nutrients-15-04586" ref-type="bibr">110</xref>]. The precise mechanisms, and the relationship to GABA levels, are yet to be understood through pre-clinical studies, but modulation within the shunt could improve the physiology of the GABA substrate, shown through reduction to GABA levels in the ROI.</p>
              <sec id="sec5dot1-nutrients-15-04586">
                <title>5.1. Limitations in This Current Study</title>
                <p>Importantly, a sample size attrition of 46% from baseline to the second time point (<italic toggle="yes">n</italic> = 8 kava; <italic toggle="yes">n</italic> = 9 placebo), resulting in the reduced power of this study overall and the reduced accuracy of predictor effects, will impact the interpretation of the results. A borderline <italic toggle="yes">p</italic>-value for the interaction terms in the model may reflect this attrition. The reporting of confidence intervals, illustrating appropriate variance ranges, may have added some support to a significant result. Although the use of linear mixed modelling is partly protective against such impacts, the results need to be considered in this context.</p>
                <p>Secondly, GABA concentration levels in the brain derived from spectral data requires high amounts of data modelling to expose GABA peaks, and there is debate on the optimal methods for sequencing, spectral analysis, quality parameters, or data modelling of ‘contaminants’ such as macromolecules. All magnify the risk of measurement errors, among other methodological issues [<xref rid="B111-nutrients-15-04586" ref-type="bibr">111</xref>,<xref rid="B112-nutrients-15-04586" ref-type="bibr">112</xref>,<xref rid="B113-nutrients-15-04586" ref-type="bibr">113</xref>]. However, an advantage was the MEGA-PRESS protocol, which is able to derive metabolite data separate from macromolecules, and the use of GANNET in the processing pipeline. Furthermore, LCModel’s toolbox-specific quality parameters could identify technical factors affecting the analysis of GABA levels. Despite removing scans of spurious quality, group differences were still observed for these variables in this current study. FWHM, as a measure of linewidth in the spectrum quantifying the signal decay rate in the time-domain as a result of shimming, was significantly different between the treatment groups. It is possible that the methods applied within the toolbox have influenced the observed GABA concentration, thereby requiring caution in interpreting the results and subsequent conclusions. However, the baseline GABA concentration was not related to FWHM, so the different quality parameters had limited impact on the reported findings.</p>
                <p>Thirdly, scan novelty may also be an influencing factor in participants with clinical anxiety. This current study did not collect data as to whether participants were familiar with MRI scan environments. A ‘sham’ scan session for each participant might have reduced this confound.</p>
                <p>For these reasons, this study’s novel findings should be considered pilot data at best, offering a novel insight into the pattern of GABA levels in a GAD as a product of Kava, as well as an example of greatly needed biomarker research for the benefit of clinical anxiety.</p>
              </sec>
              <sec id="sec5dot2-nutrients-15-04586">
                <title>5.2. Future Research Directions</title>
                <p>The findings in this study between Kava treatment, anxiety symptoms, and GABA levels warrant further examination. Given the role the dACC may play in hallmark anxiety cognition symptoms in GAD, as well as evidence of kava efficacy in the literature, it would be of value to examine whether kava-based modulations were observed on selected HAM-A items (such as cognitive over somatic symptoms), which might clarify the pattern observed in the ROI. Similarly, a division of higher anxiety and low anxiety may reveal different Kava responses. Secondly, beyond the modulation of GABA by Kava, given the likely mechanisms in the GABA metabolic shunt of Kava in preclinical studies on NMDA receptors, an examination of glutamate levels may also reveal Kava mechanisms beyond GABA, supporting recent preclinical research and offering potential avenues for future therapeutic approaches.</p>
                <p>This current study was valuable for understanding the mechanisms of Kava in GAD, and future research should extend Kava dosing in other anxiety cohorts and healthy controls and assess patterns of GABA levels in comparison with GAD. This could include major depressive disorder or state-based anxiety disorders, such as phobias and panic disorder, to delineate differences in ROI GABA levels and determine the relationship to anxiety symptoms.</p>
                <p>There remains a shortfall in brain biomarker research in anxiety disorders, especially GAD. Emerging approaches now exist to guide the identified need, such as the Research Domain Criteria (RDoC) framework [<xref rid="B114-nutrients-15-04586" ref-type="bibr">114</xref>,<xref rid="B115-nutrients-15-04586" ref-type="bibr">115</xref>], which was founded on the premise that it is insufficient to assess symptoms alone to treat (or diagnose) GAD, yet there is insufficient data serving as biomarker evidence. This current study serves to address this shortfall. Biomarker treatment approaches assert that biological patterns may not fit with current diagnostic categories, signalling a vital need for research that clarifies neurobiological marker roles in symptom maintenance and response patterns with treatment [<xref rid="B115-nutrients-15-04586" ref-type="bibr">115</xref>,<xref rid="B116-nutrients-15-04586" ref-type="bibr">116</xref>,<xref rid="B117-nutrients-15-04586" ref-type="bibr">117</xref>,<xref rid="B118-nutrients-15-04586" ref-type="bibr">118</xref>]. These markers also have potential to identify disorders before the onset of anxiety symptoms and to identify variants or clinically meaningful subsets [<xref rid="B18-nutrients-15-04586" ref-type="bibr">18</xref>,<xref rid="B119-nutrients-15-04586" ref-type="bibr">119</xref>,<xref rid="B120-nutrients-15-04586" ref-type="bibr">120</xref>]. What is measured as biomarkers in neuroimaging is arguably closer to the exact substrates that underpin disorders, and we are therefore able to more precisely gauge the relationship between biomarkers and clinical endpoints for the individual [<xref rid="B18-nutrients-15-04586" ref-type="bibr">18</xref>,<xref rid="B25-nutrients-15-04586" ref-type="bibr">25</xref>,<xref rid="B115-nutrients-15-04586" ref-type="bibr">115</xref>,<xref rid="B121-nutrients-15-04586" ref-type="bibr">121</xref>].</p>
                <p>This current study showed that GABA metabolic data were successful in producing differences that could be utilised as GAD biomarkers, with some considerations. The assessment of the neurobiological effects of Kava is novel in GAD samples and shows how our methodology could be applied to other anxiolytic phytomedicines. Data from MRS GABA can contribute to an integrative efficacy model of imaging modalities and psychological measures for future efficacy studies of biological substrates. More work is needed in the establishing of biomarkers for clinical benefit, but there is a strong translational rationale for the investigation of novel anxiolytics like Kava as GAD treatment, as demonstrated in this current study.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec6-nutrients-15-04586">
              <title>6. Conclusions</title>
              <p>In order to elucidate the role of GABA or its metabolic components either as a predisposing, preventative, or therapeutic utility, it is important to quantify GABAergic processes. This research represents the first study to assess brain GABA concentration levels in adults with GAD, as well as the first to assess modulations following a treatment intervention using Kava. This study demonstrated that GABA levels are modulated via Kava treatment, and regional brain GABA concentration levels could be linked to anxiety symptoms in GAD. The findings also indicate that GABA levels can change without concomitant changes in anxiety symptoms, suggesting that symptom profiles in GAD is complex and multi-factorial. Further studies quantifying brain anxiety markers over time, controlling for other associated variables, and the use of a benzodiazepine comparator could clarify the role of GABA as a marker of anxiety in brain regions associated with cognitive anxiety symptoms. It is also vital for future studies to determine levels of GABA in brain regions using wider healthy cohorts.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
              </fn>
            </fn-group>
            <notes>
              <title>Author Contributions</title>
              <p>K.S.: Conceptualization, Investigation, Methodology, Data curation, Formal Analysis, Writing—original draft, Writing—review and editing. J.S.: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing—review and editing. M.H.: Investigation, Methodology, Project administration, Resources, Supervisory, Writing—review and editing. C.A.B.: Investigation, Methodology, Project administration, Writing—review and editing. S.R.: Funding acquisition, Investigation, Methodology, Project administration, Resources, Writing—review and editing. A.S.: Investigation, Methodology, Project administration, Resources, Writing—review and editing. C.S.: (Con Stough) Investigation, Methodology, Project administration, Resources, Supervisory, Writing—review and editing. C.S.: (Chao Suo) Investigation, Formal Analysis, Methodology, Project administration, Resources, Supervisory, Writing—review and editing. All authors have read and agreed to the published version of the manuscript.</p>
            </notes>
            <notes>
              <title>Institutional Review Board Statement</title>
              <p>Swinburne University Human Ethics Committee (SUHREC; No. HREC2014/204), 8 August 2014.</p>
            </notes>
            <notes>
              <title>Informed Consent Statement</title>
              <p>Informed consent was obtained from all subjects involved in the study.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data Availability Statement</title>
              <p>Data were collected exclusively for the purpose of fulfilling the NHMRC grant research within a clinical group. Additionally, provision to third parties may not comply with Australian clinical trial grant mandates. To this end, the data from this study are not publicly available.</p>
            </notes>
            <notes notes-type="COI-statement">
              <title>Conflicts of Interest</title>
              <p>J. Sarris has received either presentation honoraria, travel support, clinical trial grants, book royalties, or independent consultancy payments from the following: Integria Healthcare and MediHerb (a kava product manufacturer), Pfizer, Scius Health, Key Pharmaceuticals, Taki Mai, Fiji Kava, Noetic Foundry, FIT-BioCeuticals, Blackmores, Soho-Flordis, Healthworld, HealthEd, HealthMasters, Kantar Consulting, Angelini Pharmaceuticals, Grunbiotics, Polistudium, Global Pharma Group, Australian Natural Therapeutics Group, Research Reviews, Elsevier, Chaminade University, International Society for Affective Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists, ANS, <italic toggle="yes">Society for Medicinal Plant</italic> and Natural Product Research, Sanofi-Aventis, Omega-3 Centre, the National Health and Medical Research Council, CR Roper Fellowship, and the Medical Research Futures Fund. A Scholey has received either presentation honoraria, travel support, clinical trial grants, book royalties, or independent consultancy payments from the following: Abbott Nutrition, Ārepa Nootropics, Arla Foods, Australian Research Council, Australian Wine Research Institute, Barilla, Bayer, Biotechnology and Biological Sciences Research Council, Blackmores, Coca Cola, Cognis, Cyvex, Dairy Health Innovation Consortium, Danone, Delica Therapeutics, DuPont, European Commission Framework 5 Research and Innovation initiative, Fonterra, Frutarom, GlaxoSmithKline, Ginsana, High Value Nutrition Fund, Kemin Foods, Martek, Masterfoods, National Health and Medical Research Council, Naturex, Nestlé, Neurobrands, Novartis, Nutricia-Danone, Pepsico, Pfizer, Pharmavite, Pharmaton, Red Bull, REVIV, Sanofi, Sen- Jam Pharmaceuticals, Verdure Sciences, Unilever, and the Wrigley Science Institute. He is Chief Scientific Officer for Ārepa Nootropics and is on the Scientific Advisory Board of Sen-Jam Pharmaceutical.</p>
            </notes>
            <app-group>
              <app id="app1-nutrients-15-04586">
                <title>Appendix A</title>
                <array>
                  <tbody>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">Enrolment Criteria</td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">
                        <bold>Generalised Anxiety Disorder Group</bold>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">Inclusion Criteria </td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Meets the DSM-5 diagnostic criteria for generalised anxiety disorder based on structured interview MINI 6.0.</p></list-item></list>Note that while the MINI 6.0 uses the DSM-IV criteria, the same criteria are used in the DSM-5. </td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">
                        <list list-type="bullet">
                          <list-item>
                            <p>Presentation with anxiety (HAM-A ≥ 18) at the time of study entry</p>
                          </list-item>
                          <list-item>
                            <p>Presentation of mild depressive symptoms (MADRS ≤ 18) at the time of study entry</p>
                          </list-item>
                        </list>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">Exclusion Criteria </td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">
                        <list list-type="bullet">
                          <list-item>
                            <p>Primary diagnosis other than GAD</p>
                          </list-item>
                          <list-item>
                            <p>Presentation of moderate to severe depressive symptoms (MADRS ≥ 18) at the time of study entry</p>
                          </list-item>
                          <list-item>
                            <p>Presentation of suicidal ideation (≥ 3 on MADRS suicidal thoughts domain) at the time of study entry</p>
                          </list-item>
                          <list-item>
                            <p>Current diagnosis of a psychotic disorder (bipolar disorder I, schizophrenia) on structured interview (MINI 6.0)</p>
                          </list-item>
                          <list-item>
                            <p>Current or past diagnosis of obsessive compulsive disorder or bipolar I or II disorders</p>
                          </list-item>
                          <list-item>
                            <p>Current substance/alcohol use disorder on structured interview (MINI 6.0)</p>
                          </list-item>
                          <list-item>
                            <p>Currently taking an antidepressant, mood stabiliser, antipsychotic, anticonvulsant, warfarin, or thyroxin, or regularly using a benzodiazepine or opioid-based analgesic (more than 2 days per week)</p>
                          </list-item>
                          <list-item>
                            <p>Current use of St John’s wort</p>
                          </list-item>
                          <list-item>
                            <p>Three or more failed trials of pharmacotherapy for the current GAD episode</p>
                          </list-item>
                          <list-item>
                            <p>Recently commenced psychotherapy (within four weeks of study entry)</p>
                          </list-item>
                          <list-item>
                            <p>Known or suspected clinically unstable systemic medical disorder</p>
                          </list-item>
                          <list-item>
                            <p>Pregnant or breastfeeding or trying to conceive</p>
                          </list-item>
                          <list-item>
                            <p>Not using a medically approved form of contraception (including abstinence) if female and of childbearing age</p>
                          </list-item>
                          <list-item>
                            <p>Unable to participate in all scheduled visits, treatment plan, tests, and other trial procedures according to the protocol</p>
                          </list-item>
                        </list>
                      </td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">Imaging eligibility criteria—exclusions</td>
                    </tr>
                    <tr>
                      <td align="left" valign="middle" rowspan="1" colspan="1">
                        <list list-type="bullet">
                          <list-item>
                            <p>Left-handed</p>
                          </list-item>
                          <list-item>
                            <p>Pacemaker</p>
                          </list-item>
                          <list-item>
                            <p>Infusion pumps</p>
                          </list-item>
                          <list-item>
                            <p>Aneurysm clips</p>
                          </list-item>
                          <list-item>
                            <p>Metal prostheses</p>
                          </list-item>
                          <list-item>
                            <p>Metal joints</p>
                          </list-item>
                          <list-item>
                            <p>Metal rods</p>
                          </list-item>
                          <list-item>
                            <p>Metal plates</p>
                          </list-item>
                          <list-item>
                            <p>Metal staples</p>
                          </list-item>
                          <list-item>
                            <p>Non-removable body piercings</p>
                          </list-item>
                          <list-item>
                            <p>Persons who have worked as welders or may have metal splinters in their body</p>
                          </list-item>
                          <list-item>
                            <p>Females: taking hormone-modulating contraception including oral contraceptive pill or implants</p>
                          </list-item>
                          <list-item>
                            <p>Females: irregular menstrual cycle in order to ascertain days 1–10 for the conducting of scans</p>
                          </list-item>
                        </list>
                      </td>
                    </tr>
                  </tbody>
                </array>
              </app>
            </app-group>
            <ref-list>
              <title>References</title>
              <ref id="B1-nutrients-15-04586">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Merikangas</surname>
                      <given-names>K.R.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Avenevoli</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Acharyya</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Neuenschwander</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Angst</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Longitudinal Trajectories of Depression and Anxiety in a Prospective Community Study: The Zurich Cohort Study</article-title>
                  <source>Arch. Gen. Psychiatry</source>
                  <year>2003</year>
                  <volume>60</volume>
                  <fpage>993</fpage>
                  <lpage>1000</lpage>
                  <pub-id pub-id-type="doi">10.1001/archpsyc.60.9.993</pub-id>
                  <pub-id pub-id-type="pmid">14557144</pub-id>
                </element-citation>
              </ref>
              <ref id="B2-nutrients-15-04586">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wittchen</surname>
                      <given-names>H.U.</given-names>
                    </name>
                    <name>
                      <surname>Zhao</surname>
                      <given-names>S.Y.</given-names>
                    </name>
                    <name>
                      <surname>Kessler</surname>
                      <given-names>R.C.</given-names>
                    </name>
                    <name>
                      <surname>Eaton</surname>
                      <given-names>W.W.</given-names>
                    </name>
                  </person-group>
                  <article-title>DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey</article-title>
                  <source>Arch. Gen. Psychiatry</source>
                  <year>1994</year>
                  <volume>51</volume>
                  <fpage>355</fpage>
                  <lpage>364</lpage>
                  <pub-id pub-id-type="doi">10.1001/archpsyc.1994.03950050015002</pub-id>
                  <?supplied-pmid 8179459?>
                  <pub-id pub-id-type="pmid">8179459</pub-id>
                </element-citation>
              </ref>
              <ref id="B3-nutrients-15-04586">
                <label>3.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>American Psychiatric Association</collab>
                  </person-group>
                  <source>Diagnostic and Statistical Manual of Mental Disorders</source>
                  <edition>5th ed.</edition>
                  <comment>Text Revision</comment>
                  <publisher-name>American Psychiatric Press</publisher-name>
                  <publisher-loc>Washington, DC, USA</publisher-loc>
                  <year>2022</year>
                </element-citation>
              </ref>
              <ref id="B4-nutrients-15-04586">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barlow</surname>
                      <given-names>D.H.</given-names>
                    </name>
                    <name>
                      <surname>Wincze</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>DSM-IV and beyond: What is generalized anxiety disorder?</article-title>
                  <source>Acta Psychiatr. Scand.</source>
                  <year>1998</year>
                  <volume>98</volume>
                  <fpage>23</fpage>
                  <lpage>29</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1600-0447.1998.tb05962.x</pub-id>
                  <?supplied-pmid 9777043?>
                  <pub-id pub-id-type="pmid">9696510</pub-id>
                </element-citation>
              </ref>
              <ref id="B5-nutrients-15-04586">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Freedman</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Lewis</surname>
                      <given-names>D.A.</given-names>
                    </name>
                    <name>
                      <surname>Michels</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Pine</surname>
                      <given-names>D.S.</given-names>
                    </name>
                    <name>
                      <surname>Schultz</surname>
                      <given-names>S.K.</given-names>
                    </name>
                    <name>
                      <surname>Tamminga</surname>
                      <given-names>C.A.</given-names>
                    </name>
                    <name>
                      <surname>Yager</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>The initial field trials of DSM-5: New blooms and old thorns</article-title>
                  <source>Am. J. Psychiatry</source>
                  <year>2013</year>
                  <volume>170</volume>
                  <fpage>1</fpage>
                  <lpage>5</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.ajp.2012.12091189</pub-id>
                  <?supplied-pmid 23288382?>
                  <pub-id pub-id-type="pmid">23288382</pub-id>
                </element-citation>
              </ref>
              <ref id="B6-nutrients-15-04586">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Starcevic</surname>
                      <given-names>V.</given-names>
                    </name>
                  </person-group>
                  <article-title>Generalized anxiety disorder: Psychopharmacotherapy update on a common and commonly overlooked condition</article-title>
                  <source>Australas Psychiatry</source>
                  <year>2015</year>
                  <volume>23</volume>
                  <fpage>338</fpage>
                  <lpage>342</lpage>
                  <pub-id pub-id-type="doi">10.1177/1039856215587233</pub-id>
                  <?supplied-pmid 26023165?>
                  <pub-id pub-id-type="pmid">26023165</pub-id>
                </element-citation>
              </ref>
              <ref id="B7-nutrients-15-04586">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stein</surname>
                      <given-names>M.B.</given-names>
                    </name>
                    <name>
                      <surname>Sareen</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical Practice. Generalized Anxiety Disorder</article-title>
                  <source>New Engl. J. Med.</source>
                  <year>2015</year>
                  <volume>373</volume>
                  <fpage>2059</fpage>
                  <lpage>2068</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMcp1502514</pub-id>
                  <?supplied-pmid 26580998?>
                  <pub-id pub-id-type="pmid">26580998</pub-id>
                </element-citation>
              </ref>
              <ref id="B8-nutrients-15-04586">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cuijpers</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Sijbrandij</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Koole</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Huibers</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Berking</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Andersson</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Psychological treatment of generalized anxiety disorder: A meta-analysis</article-title>
                  <source>Clin. Psychol. Rev.</source>
                  <year>2014</year>
                  <volume>34</volume>
                  <fpage>130</fpage>
                  <lpage>140</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cpr.2014.01.002</pub-id>
                  <?supplied-pmid 24487344?>
                  <pub-id pub-id-type="pmid">24487344</pub-id>
                </element-citation>
              </ref>
              <ref id="B9-nutrients-15-04586">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baldwin</surname>
                      <given-names>D.S.</given-names>
                    </name>
                    <name>
                      <surname>Waldman</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Allgulander</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Evidence-based pharmacological treatment of generalized anxiety disorder</article-title>
                  <source>Int. J. Neuropsychopharmacol.</source>
                  <year>2011</year>
                  <volume>14</volume>
                  <fpage>697</fpage>
                  <lpage>710</lpage>
                  <pub-id pub-id-type="doi">10.1017/S1461145710001434</pub-id>
                  <pub-id pub-id-type="pmid">21211105</pub-id>
                </element-citation>
              </ref>
              <ref id="B10-nutrients-15-04586">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Slee</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Nazareth</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Bondaronek</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Freemantle</surname>
                      <given-names>N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis</article-title>
                  <source>Lancet</source>
                  <year>2019</year>
                  <volume>393</volume>
                  <fpage>768</fpage>
                  <lpage>777</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31793-8</pub-id>
                  <pub-id pub-id-type="pmid">30712879</pub-id>
                </element-citation>
              </ref>
              <ref id="B11-nutrients-15-04586">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gale</surname>
                      <given-names>C.K.</given-names>
                    </name>
                    <name>
                      <surname>Millichamp</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Generalised anxiety disorder</article-title>
                  <source>BMJ Clin. Evid.</source>
                  <year>2011</year>
                  <volume>2011</volume>
                  <fpage>1002</fpage>
                </element-citation>
              </ref>
              <ref id="B12-nutrients-15-04586">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gale</surname>
                      <given-names>C.K.</given-names>
                    </name>
                    <name>
                      <surname>Millichamp</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Generalised anxiety disorder in children and adolescents</article-title>
                  <source>BMJ Clin. Evid.</source>
                  <year>2016</year>
                  <volume>2016</volume>
                  <fpage>1002</fpage>
                  <?supplied-pmid 26763675?>
                  <pub-id pub-id-type="pmid">26763675</pub-id>
                </element-citation>
              </ref>
              <ref id="B13-nutrients-15-04586">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gunter</surname>
                      <given-names>R.W.</given-names>
                    </name>
                    <name>
                      <surname>Whittal</surname>
                      <given-names>M.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Dissemination of cognitive-behavioral treatments for anxiety disorders: Overcoming barriers and improving patient access</article-title>
                  <source>Clin. Psychol. Rev.</source>
                  <year>2010</year>
                  <volume>30</volume>
                  <fpage>194</fpage>
                  <lpage>202</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cpr.2009.11.001</pub-id>
                  <?supplied-pmid 19942331?>
                  <pub-id pub-id-type="pmid">19942331</pub-id>
                </element-citation>
              </ref>
              <ref id="B14-nutrients-15-04586">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoffman</surname>
                      <given-names>E.J.</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>S.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Anxiety disorders: A comprehensive review of pharmacotherapies</article-title>
                  <source>Mt. Sinai J. Med.</source>
                  <year>2008</year>
                  <volume>75</volume>
                  <fpage>248</fpage>
                  <lpage>262</lpage>
                  <pub-id pub-id-type="doi">10.1002/msj.20041</pub-id>
                  <pub-id pub-id-type="pmid">18704983</pub-id>
                </element-citation>
              </ref>
              <ref id="B15-nutrients-15-04586">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nasir</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Trujillo</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Levine</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Dwyer</surname>
                      <given-names>J.B.</given-names>
                    </name>
                    <name>
                      <surname>Rupp</surname>
                      <given-names>Z.W.</given-names>
                    </name>
                    <name>
                      <surname>Bloch</surname>
                      <given-names>M.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology</article-title>
                  <source>Front. Psychiatry</source>
                  <year>2020</year>
                  <volume>11</volume>
                  <fpage>548505</fpage>
                  <pub-id pub-id-type="doi">10.3389/fpsyt.2020.548505</pub-id>
                  <?supplied-pmid 33329087?>
                  <pub-id pub-id-type="pmid">33329087</pub-id>
                </element-citation>
              </ref>
              <ref id="B16-nutrients-15-04586">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weisberg</surname>
                      <given-names>R.B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Overview of generalized anxiety disorder: Epidemiology, presentation, and course</article-title>
                  <source>J. Clin. Psychiatry</source>
                  <year>2009</year>
                  <volume>70</volume>
                  <issue>(Suppl. 2)</issue>
                  <fpage>4</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.4088/JCP.s.7002.01</pub-id>
                  <?supplied-pmid 19371500?>
                  <pub-id pub-id-type="pmid">19371500</pub-id>
                </element-citation>
              </ref>
              <ref id="B17-nutrients-15-04586">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Farach</surname>
                      <given-names>F.J.</given-names>
                    </name>
                    <name>
                      <surname>Pruitt</surname>
                      <given-names>L.D.</given-names>
                    </name>
                    <name>
                      <surname>Jun</surname>
                      <given-names>J.J.</given-names>
                    </name>
                    <name>
                      <surname>Jerud</surname>
                      <given-names>A.B.</given-names>
                    </name>
                    <name>
                      <surname>Zoellner</surname>
                      <given-names>L.A.</given-names>
                    </name>
                    <name>
                      <surname>Roy-Byrne</surname>
                      <given-names>P.P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacological treatment of anxiety disorders: Current treatments and future directions</article-title>
                  <source>J. Anxiety Disord.</source>
                  <year>2012</year>
                  <volume>26</volume>
                  <fpage>833</fpage>
                  <lpage>843</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.janxdis.2012.07.009</pub-id>
                  <?supplied-pmid 23023162?>
                  <pub-id pub-id-type="pmid">23023162</pub-id>
                </element-citation>
              </ref>
              <ref id="B18-nutrients-15-04586">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kapur</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Phillips</surname>
                      <given-names>A.G.</given-names>
                    </name>
                    <name>
                      <surname>Insel</surname>
                      <given-names>T.R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?</article-title>
                  <source>Mol. Psychiatry</source>
                  <year>2012</year>
                  <volume>17</volume>
                  <fpage>1174</fpage>
                  <lpage>1179</lpage>
                  <pub-id pub-id-type="doi">10.1038/mp.2012.105</pub-id>
                  <?supplied-pmid 22869033?>
                  <pub-id pub-id-type="pmid">22869033</pub-id>
                </element-citation>
              </ref>
              <ref id="B19-nutrients-15-04586">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Is pharma running out of brainy ideas?</article-title>
                  <source>Science</source>
                  <year>2010</year>
                  <volume>329</volume>
                  <fpage>502</fpage>
                  <lpage>504</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.329.5991.502</pub-id>
                  <pub-id pub-id-type="pmid">20671165</pub-id>
                </element-citation>
              </ref>
              <ref id="B20-nutrients-15-04586">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murrough</surname>
                      <given-names>J.W.</given-names>
                    </name>
                    <name>
                      <surname>Yaqubi</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Sayed</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Charney</surname>
                      <given-names>D.S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Emerging drugs for the treatment of anxiety</article-title>
                  <source>Expert Opin. Emerg. Drugs</source>
                  <year>2015</year>
                  <volume>20</volume>
                  <fpage>393</fpage>
                  <lpage>406</lpage>
                  <pub-id pub-id-type="doi">10.1517/14728214.2015.1049996</pub-id>
                  <pub-id pub-id-type="pmid">26012843</pub-id>
                </element-citation>
              </ref>
              <ref id="B21-nutrients-15-04586">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sartori</surname>
                      <given-names>S.B.</given-names>
                    </name>
                    <name>
                      <surname>Singewald</surname>
                      <given-names>N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders</article-title>
                  <source>Pharmacol. Ther.</source>
                  <year>2019</year>
                  <volume>204</volume>
                  <fpage>107402</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.107402</pub-id>
                  <pub-id pub-id-type="pmid">31470029</pub-id>
                </element-citation>
              </ref>
              <ref id="B22-nutrients-15-04586">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sarris</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>McIntyre</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Camfield</surname>
                      <given-names>D.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Plant-based medicines for anxiety disorders, part 1: A review of preclinical studies</article-title>
                  <source>CNS Drugs</source>
                  <year>2013</year>
                  <volume>27</volume>
                  <fpage>207</fpage>
                  <lpage>219</lpage>
                  <pub-id pub-id-type="doi">10.1007/s40263-013-0044-3</pub-id>
                  <?supplied-pmid 23436255?>
                  <pub-id pub-id-type="pmid">23436255</pub-id>
                </element-citation>
              </ref>
              <ref id="B23-nutrients-15-04586">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Savage</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Firth</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Stough</surname>
                      <given-names>C.K.</given-names>
                    </name>
                    <name>
                      <surname>Sarris</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence</article-title>
                  <source>Phytother. Res.</source>
                  <year>2017</year>
                  <volume>32</volume>
                  <fpage>3</fpage>
                  <lpage>18</lpage>
                  <pub-id pub-id-type="doi">10.1002/ptr.5940</pub-id>
                  <?supplied-pmid 29168225?>
                  <pub-id pub-id-type="pmid">29168225</pub-id>
                </element-citation>
              </ref>
              <ref id="B24-nutrients-15-04586">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bandelow</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Michaelis</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Wedekind</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment of anxiety disorders</article-title>
                  <source>Dialogues Clin. Neurosci.</source>
                  <year>2017</year>
                  <volume>19</volume>
                  <fpage>93</fpage>
                  <lpage>107</lpage>
                  <pub-id pub-id-type="doi">10.31887/DCNS.2017.19.2/bbandelow</pub-id>
                  <?supplied-pmid 28867934?>
                  <pub-id pub-id-type="pmid">28867934</pub-id>
                </element-citation>
              </ref>
              <ref id="B25-nutrients-15-04586">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bandelow</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Baldwin</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Abelli</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Bolea-Alamanac</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Bourin</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Chamberlain</surname>
                      <given-names>S.R.</given-names>
                    </name>
                    <name>
                      <surname>Riederer</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition</article-title>
                  <source>World J. Biol. Psychiatry</source>
                  <year>2017</year>
                  <volume>18</volume>
                  <fpage>162</fpage>
                  <lpage>214</lpage>
                  <pub-id pub-id-type="doi">10.1080/15622975.2016.1190867</pub-id>
                  <?supplied-pmid 27419272?>
                  <pub-id pub-id-type="pmid">27419272</pub-id>
                </element-citation>
              </ref>
              <ref id="B26-nutrients-15-04586">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferreira-Garcia</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Mochcovitch</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>do Cabo</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Nardi</surname>
                      <given-names>A.E.</given-names>
                    </name>
                    <name>
                      <surname>Freire</surname>
                      <given-names>R.C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Predictors of pharmacotherapy response in generalized anxiety disorder: A systematic review</article-title>
                  <source>Harv. Rev. Psychiatry</source>
                  <year>2017</year>
                  <volume>25</volume>
                  <fpage>65</fpage>
                  <lpage>79</lpage>
                  <pub-id pub-id-type="doi">10.1097/HRP.0000000000000127</pub-id>
                  <?supplied-pmid 28272131?>
                  <pub-id pub-id-type="pmid">28272131</pub-id>
                </element-citation>
              </ref>
              <ref id="B27-nutrients-15-04586">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maron</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Nutt</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Biological Markers of Generalized Anxiety Disorder</article-title>
                  <source>Focus</source>
                  <year>2018</year>
                  <volume>16</volume>
                  <fpage>210</fpage>
                  <lpage>218</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.focus.16205</pub-id>
                  <?supplied-pmid 32015708?>
                  <pub-id pub-id-type="pmid">32015708</pub-id>
                </element-citation>
              </ref>
              <ref id="B28-nutrients-15-04586">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Strawn</surname>
                      <given-names>J.R.</given-names>
                    </name>
                    <name>
                      <surname>Levine</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment response biomarkers in anxiety disorders: From neuroimaging to neuronally-derived extracellular vesicles and beyond</article-title>
                  <source>Biomark. Neuropsychiatry</source>
                  <year>2020</year>
                  <volume>3</volume>
                  <elocation-id>100024</elocation-id>
                  <pub-id pub-id-type="doi">10.1016/j.bionps.2020.100024</pub-id>
                  <pub-id pub-id-type="pmid">32974615</pub-id>
                </element-citation>
              </ref>
              <ref id="B29-nutrients-15-04586">
                <label>29.</label>
                <element-citation publication-type="confproc">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hayashi</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Nagai</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Action of ω-amino acids on the motor cortex of higher animals, especially γ-amino-β-oxybutyric acid as the real inhibitory principle in brain</article-title>
                  <source>Proceedings of the Twentieth International Physiological Congress</source>
                  <conf-loc>Brussels, Belgium</conf-loc>
                  <conf-date>March 1955–January 1956</conf-date>
                </element-citation>
              </ref>
              <ref id="B30-nutrients-15-04586">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Killam</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Bain</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Convulsant hydrazides I: In vitro and in vivo inhibition of vitamin B6 enzymes by convulsant hydrazides</article-title>
                  <source>J. Pharmacol. Exp. Ther.</source>
                  <year>1957</year>
                  <volume>119</volume>
                  <fpage>255</fpage>
                  <lpage>262</lpage>
                  <pub-id pub-id-type="pmid">13417077</pub-id>
                </element-citation>
              </ref>
              <ref id="B31-nutrients-15-04586">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Etkin</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Wager</surname>
                      <given-names>T.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia</article-title>
                  <source>Am. J. Psychiatry</source>
                  <year>2007</year>
                  <volume>164</volume>
                  <fpage>1476</fpage>
                  <lpage>1488</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.ajp.2007.07030504</pub-id>
                  <pub-id pub-id-type="pmid">17898336</pub-id>
                </element-citation>
              </ref>
              <ref id="B32-nutrients-15-04586">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nuss</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Anxiety disorders and GABA neurotransmission: A disturbance of modulation</article-title>
                  <source>Neuropsychiatr. Dis. Treat.</source>
                  <year>2015</year>
                  <volume>11</volume>
                  <fpage>165</fpage>
                  <lpage>175</lpage>
                  <pub-id pub-id-type="doi">10.2147/NDT.S58841</pub-id>
                  <pub-id pub-id-type="pmid">25653526</pub-id>
                </element-citation>
              </ref>
              <ref id="B33-nutrients-15-04586">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Northoff</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Walter</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Schulte</surname>
                      <given-names>R.F.</given-names>
                    </name>
                    <name>
                      <surname>Beck</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Dydak</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Henning</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Boesiger</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI</article-title>
                  <source>Nat. Neurosci.</source>
                  <year>2007</year>
                  <volume>10</volume>
                  <fpage>1515</fpage>
                  <lpage>1517</lpage>
                  <pub-id pub-id-type="doi">10.1038/nn2001</pub-id>
                  <?supplied-pmid 17982452?>
                  <pub-id pub-id-type="pmid">17982452</pub-id>
                </element-citation>
              </ref>
              <ref id="B34-nutrients-15-04586">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Puts</surname>
                      <given-names>N.A.J.</given-names>
                    </name>
                    <name>
                      <surname>Edden</surname>
                      <given-names>R.A.E.</given-names>
                    </name>
                  </person-group>
                  <article-title>In vivo magnetic resonance spectroscopy of GABA: A methodological review</article-title>
                  <source>Prog. Nucl. Magn. Reson. Spectrosc.</source>
                  <year>2012</year>
                  <volume>60</volume>
                  <fpage>29</fpage>
                  <lpage>41</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pnmrs.2011.06.001</pub-id>
                  <?supplied-pmid 22293397?>
                  <pub-id pub-id-type="pmid">22293397</pub-id>
                </element-citation>
              </ref>
              <ref id="B35-nutrients-15-04586">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rae</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra</article-title>
                  <source>Neurochem. Res.</source>
                  <year>2014</year>
                  <volume>39</volume>
                  <fpage>1</fpage>
                  <lpage>36</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11064-013-1199-5</pub-id>
                  <?supplied-pmid 24258018?>
                  <pub-id pub-id-type="pmid">24258018</pub-id>
                </element-citation>
              </ref>
              <ref id="B36-nutrients-15-04586">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tasan</surname>
                      <given-names>R.O.</given-names>
                    </name>
                    <name>
                      <surname>Bukovac</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Peterschmitt</surname>
                      <given-names>Y.N.</given-names>
                    </name>
                    <name>
                      <surname>Sartori</surname>
                      <given-names>S.B.</given-names>
                    </name>
                    <name>
                      <surname>Landgraf</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Singewald</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Sperk</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Altered GABA transmission in a mouse model of increased trait anxiety</article-title>
                  <source>Neuroscience</source>
                  <year>2011</year>
                  <volume>183</volume>
                  <fpage>71</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.03.051</pub-id>
                  <pub-id pub-id-type="pmid">21458543</pub-id>
                </element-citation>
              </ref>
              <ref id="B37-nutrients-15-04586">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nemeroff</surname>
                      <given-names>C.B.</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of GABA in the pathophysiology and treatment of anxiety disorders</article-title>
                  <source>Psychopharmacol. Bull.</source>
                  <year>2003</year>
                  <volume>37</volume>
                  <fpage>133</fpage>
                  <lpage>146</lpage>
                  <?supplied-pmid 15131523?>
                  <pub-id pub-id-type="pmid">15131523</pub-id>
                </element-citation>
              </ref>
              <ref id="B38-nutrients-15-04586">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nutt</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Malizia</surname>
                      <given-names>A.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder</article-title>
                  <source>Br. J. Psychiatry</source>
                  <year>2001</year>
                  <volume>179</volume>
                  <fpage>390</fpage>
                  <lpage>396</lpage>
                  <pub-id pub-id-type="doi">10.1192/bjp.179.5.390</pub-id>
                  <?supplied-pmid 11689393?>
                  <pub-id pub-id-type="pmid">11689393</pub-id>
                </element-citation>
              </ref>
              <ref id="B39-nutrients-15-04586">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schur</surname>
                      <given-names>R.R.</given-names>
                    </name>
                    <name>
                      <surname>Draisma</surname>
                      <given-names>L.W.</given-names>
                    </name>
                    <name>
                      <surname>Wijnen</surname>
                      <given-names>J.P.</given-names>
                    </name>
                    <name>
                      <surname>Boks</surname>
                      <given-names>M.P.</given-names>
                    </name>
                    <name>
                      <surname>Koevoets</surname>
                      <given-names>M.G.</given-names>
                    </name>
                    <name>
                      <surname>Joels</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Vinkers</surname>
                      <given-names>C.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies</article-title>
                  <source>Hum. Brain Mapp.</source>
                  <year>2016</year>
                  <volume>37</volume>
                  <fpage>3337</fpage>
                  <lpage>3352</lpage>
                  <pub-id pub-id-type="doi">10.1002/hbm.23244</pub-id>
                  <?supplied-pmid 27145016?>
                  <pub-id pub-id-type="pmid">27145016</pub-id>
                </element-citation>
              </ref>
              <ref id="B40-nutrients-15-04586">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Delli Pizzi</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Padulo</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Brancucci</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Bubbico</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Edden</surname>
                      <given-names>R.A.</given-names>
                    </name>
                    <name>
                      <surname>Ferretti</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Bonanni</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>GABA content within the ventromedial prefrontal cortex is related to trait anxiety</article-title>
                  <source>Soc. Cogn. Affect. Neurosci.</source>
                  <year>2015</year>
                  <volume>11</volume>
                  <fpage>758</fpage>
                  <lpage>766</lpage>
                  <pub-id pub-id-type="doi">10.1093/scan/nsv155</pub-id>
                  <pub-id pub-id-type="pmid">26722018</pub-id>
                </element-citation>
              </ref>
              <ref id="B41-nutrients-15-04586">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Michels</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Schulte-Vels</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Schick</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>O’Gorman</surname>
                      <given-names>R.L.</given-names>
                    </name>
                    <name>
                      <surname>Zeffiro</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Hasler</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Mueller-Pfeiffer</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Prefrontal GABA and glutathione imbalance in posttraumatic stress disorder: Preliminary findings</article-title>
                  <source>Psychiatry Res. Neuroimaging</source>
                  <year>2014</year>
                  <volume>224</volume>
                  <fpage>288</fpage>
                  <lpage>295</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pscychresns.2014.09.007</pub-id>
                </element-citation>
              </ref>
              <ref id="B42-nutrients-15-04586">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pennington</surname>
                      <given-names>D.L.</given-names>
                    </name>
                    <name>
                      <surname>Abé</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Batki</surname>
                      <given-names>S.L.</given-names>
                    </name>
                    <name>
                      <surname>Meyerhoff</surname>
                      <given-names>D.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder</article-title>
                  <source>Psychiatry Res.</source>
                  <year>2014</year>
                  <volume>224</volume>
                  <fpage>281</fpage>
                  <lpage>287</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pscychresns.2014.09.004</pub-id>
                  <pub-id pub-id-type="pmid">25444536</pub-id>
                </element-citation>
              </ref>
              <ref id="B43-nutrients-15-04586">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rosso</surname>
                      <given-names>I.M.</given-names>
                    </name>
                    <name>
                      <surname>Weiner</surname>
                      <given-names>M.R.</given-names>
                    </name>
                    <name>
                      <surname>Crowley</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Silveri</surname>
                      <given-names>M.M.</given-names>
                    </name>
                    <name>
                      <surname>Rauch</surname>
                      <given-names>S.L.</given-names>
                    </name>
                    <name>
                      <surname>Jensen</surname>
                      <given-names>J.E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Insula and anterior cingulate GABA levels in posttraumatic stress disorder: Preliminary findings using magnetic resonance spectroscopy</article-title>
                  <source>Depress. Anxiety</source>
                  <year>2014</year>
                  <volume>31</volume>
                  <fpage>115</fpage>
                  <lpage>123</lpage>
                  <pub-id pub-id-type="doi">10.1002/da.22155</pub-id>
                  <?supplied-pmid 23861191?>
                  <pub-id pub-id-type="pmid">23861191</pub-id>
                </element-citation>
              </ref>
              <ref id="B44-nutrients-15-04586">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Goddard</surname>
                      <given-names>A.W.</given-names>
                    </name>
                    <name>
                      <surname>Mason</surname>
                      <given-names>G.F.</given-names>
                    </name>
                    <name>
                      <surname>Almai</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Rothman</surname>
                      <given-names>D.L.</given-names>
                    </name>
                    <name>
                      <surname>Behar</surname>
                      <given-names>K.L.</given-names>
                    </name>
                    <name>
                      <surname>Petroff</surname>
                      <given-names>O.A.</given-names>
                    </name>
                    <name>
                      <surname>Krystal</surname>
                      <given-names>J.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy</article-title>
                  <source>Arch. Gen. Psychiatry</source>
                  <year>2001</year>
                  <volume>58</volume>
                  <fpage>556</fpage>
                  <lpage>561</lpage>
                  <pub-id pub-id-type="doi">10.1001/archpsyc.58.6.556</pub-id>
                  <pub-id pub-id-type="pmid">11386984</pub-id>
                </element-citation>
              </ref>
              <ref id="B45-nutrients-15-04586">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ham</surname>
                      <given-names>B.-J.</given-names>
                    </name>
                    <name>
                      <surname>Sung</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>J.E.</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Lyoo</surname>
                      <given-names>I.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: A proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) study</article-title>
                  <source>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</source>
                  <year>2007</year>
                  <volume>31</volume>
                  <fpage>403</fpage>
                  <lpage>411</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.10.011</pub-id>
                  <?supplied-pmid 17141385?>
                  <pub-id pub-id-type="pmid">17141385</pub-id>
                </element-citation>
              </ref>
              <ref id="B46-nutrients-15-04586">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hasler</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>van der Veen</surname>
                      <given-names>J.W.</given-names>
                    </name>
                    <name>
                      <surname>Geraci</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Shen</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Pine</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Drevets</surname>
                      <given-names>W.C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Prefrontal cortical gamma-aminobutyric Acid levels in panic disorder determined by proton magnetic resonance spectroscopy</article-title>
                  <source>Biol. Psychiatry</source>
                  <year>2009</year>
                  <volume>65</volume>
                  <fpage>273</fpage>
                  <lpage>275</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.06.023</pub-id>
                  <?supplied-pmid 18692172?>
                  <pub-id pub-id-type="pmid">18692172</pub-id>
                </element-citation>
              </ref>
              <ref id="B47-nutrients-15-04586">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pollack</surname>
                      <given-names>M.H.</given-names>
                    </name>
                    <name>
                      <surname>Jensen</surname>
                      <given-names>J.E.</given-names>
                    </name>
                    <name>
                      <surname>Simon</surname>
                      <given-names>N.M.</given-names>
                    </name>
                    <name>
                      <surname>Kaufman</surname>
                      <given-names>R.E.</given-names>
                    </name>
                    <name>
                      <surname>Renshaw</surname>
                      <given-names>P.F.</given-names>
                    </name>
                  </person-group>
                  <article-title>High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: Response to treatment with levetiracetam</article-title>
                  <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source>
                  <year>2008</year>
                  <volume>32</volume>
                  <fpage>739</fpage>
                  <lpage>743</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.11.023</pub-id>
                  <?supplied-pmid 18206286?>
                  <pub-id pub-id-type="pmid">18206286</pub-id>
                </element-citation>
              </ref>
              <ref id="B48-nutrients-15-04586">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abdallah</surname>
                      <given-names>C.G.</given-names>
                    </name>
                    <name>
                      <surname>Coplan</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Jackowski</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Sato</surname>
                      <given-names>J.R.</given-names>
                    </name>
                    <name>
                      <surname>Mao</surname>
                      <given-names>X.</given-names>
                    </name>
                    <name>
                      <surname>Shungu</surname>
                      <given-names>D.C.</given-names>
                    </name>
                    <name>
                      <surname>Mathew</surname>
                      <given-names>S.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD</article-title>
                  <source>Eur. Neuropsychopharmacol.</source>
                  <year>2013</year>
                  <volume>23</volume>
                  <fpage>276</fpage>
                  <lpage>284</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.euroneuro.2012.05.009</pub-id>
                  <?supplied-pmid 22739126?>
                  <pub-id pub-id-type="pmid">22739126</pub-id>
                </element-citation>
              </ref>
              <ref id="B49-nutrients-15-04586">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mathew</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Price</surname>
                      <given-names>R.B.</given-names>
                    </name>
                    <name>
                      <surname>Mao</surname>
                      <given-names>X.</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>E.L.</given-names>
                    </name>
                    <name>
                      <surname>Coplan</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Charney</surname>
                      <given-names>D.S.</given-names>
                    </name>
                    <name>
                      <surname>Shungu</surname>
                      <given-names>D.C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder</article-title>
                  <source>Biol. Psychiatry</source>
                  <year>2008</year>
                  <volume>63</volume>
                  <fpage>891</fpage>
                  <lpage>898</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biopsych.2007.09.012</pub-id>
                  <pub-id pub-id-type="pmid">18028881</pub-id>
                </element-citation>
              </ref>
              <ref id="B50-nutrients-15-04586">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mathew</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Price</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Shungu</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Mao</surname>
                      <given-names>X.</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Amiel</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Coplan</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>A pilot study of the effects of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety disorder</article-title>
                  <source>J. Psychopharmacol.</source>
                  <year>2010</year>
                  <volume>24</volume>
                  <fpage>1175</fpage>
                  <lpage>1181</lpage>
                  <pub-id pub-id-type="doi">10.1177/0269881108101796</pub-id>
                  <pub-id pub-id-type="pmid">19204062</pub-id>
                </element-citation>
              </ref>
              <ref id="B51-nutrients-15-04586">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bush</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Luu</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Posner</surname>
                      <given-names>M.I.</given-names>
                    </name>
                  </person-group>
                  <article-title>Cognitive and emotional influences in anterior cingulate cortex</article-title>
                  <source>Trends Cogn. Sci.</source>
                  <year>2000</year>
                  <volume>4</volume>
                  <fpage>215</fpage>
                  <lpage>222</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1364-6613(00)01483-2</pub-id>
                  <pub-id pub-id-type="pmid">10827444</pub-id>
                </element-citation>
              </ref>
              <ref id="B52-nutrients-15-04586">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Critchley</surname>
                      <given-names>H.D.</given-names>
                    </name>
                    <name>
                      <surname>Mathias</surname>
                      <given-names>C.J.</given-names>
                    </name>
                    <name>
                      <surname>Josephs</surname>
                      <given-names>O.</given-names>
                    </name>
                    <name>
                      <surname>O’Doherty</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Zanini</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Dewar</surname>
                      <given-names>B.K.</given-names>
                    </name>
                    <name>
                      <surname>Dolan</surname>
                      <given-names>R.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Human cingulate cortex and autonomic control: Converging neuroimaging and clinical evidence</article-title>
                  <source>Brain</source>
                  <year>2003</year>
                  <volume>126</volume>
                  <fpage>2139</fpage>
                  <lpage>2152</lpage>
                  <pub-id pub-id-type="doi">10.1093/brain/awg216</pub-id>
                  <pub-id pub-id-type="pmid">12821513</pub-id>
                </element-citation>
              </ref>
              <ref id="B53-nutrients-15-04586">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Etkin</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Egner</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Kalisch</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Emotional processing in anterior cingulate and medial prefrontal cortex</article-title>
                  <source>Trends Cogn. Sci.</source>
                  <year>2011</year>
                  <volume>15</volume>
                  <fpage>85</fpage>
                  <lpage>93</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.tics.2010.11.004</pub-id>
                  <?supplied-pmid 21167765?>
                  <pub-id pub-id-type="pmid">21167765</pub-id>
                </element-citation>
              </ref>
              <ref id="B54-nutrients-15-04586">
                <label>54.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Luu</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Pederson</surname>
                      <given-names>S.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>The anterior cingulate cortex: Regulating actions in context</article-title>
                  <source>Cognitive Neuroscience of Attention</source>
                  <publisher-name>Guilford Publication, Inc.</publisher-name>
                  <publisher-loc>New York, NY, USA</publisher-loc>
                  <year>2004</year>
                  <fpage>232</fpage>
                  <lpage>242</lpage>
                </element-citation>
              </ref>
              <ref id="B55-nutrients-15-04586">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vogt</surname>
                      <given-names>B.A.</given-names>
                    </name>
                    <name>
                      <surname>Finch</surname>
                      <given-names>D.M.</given-names>
                    </name>
                    <name>
                      <surname>Olson</surname>
                      <given-names>C.R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Functional heterogeneity in cingulate cortex: The anterior executive and posterior evaluative regions</article-title>
                  <source>Cereb. Cortex</source>
                  <year>1992</year>
                  <volume>2</volume>
                  <fpage>435</fpage>
                  <lpage>443</lpage>
                  <pub-id pub-id-type="doi">10.1093/cercor/2.6.435-a</pub-id>
                  <?supplied-pmid 1477524?>
                  <pub-id pub-id-type="pmid">1477524</pub-id>
                </element-citation>
              </ref>
              <ref id="B56-nutrients-15-04586">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buckner</surname>
                      <given-names>R.L.</given-names>
                    </name>
                    <name>
                      <surname>Andrews-Hanna</surname>
                      <given-names>J.R.</given-names>
                    </name>
                    <name>
                      <surname>Schacter</surname>
                      <given-names>D.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>The brain’s default network: Anatomy, function, and relevance to disease</article-title>
                  <source>Ann. N. Y. Acad. Sci.</source>
                  <year>2008</year>
                  <volume>1124</volume>
                  <fpage>1</fpage>
                  <lpage>38</lpage>
                  <pub-id pub-id-type="doi">10.1196/annals.1440.011</pub-id>
                  <?supplied-pmid 18400922?>
                  <pub-id pub-id-type="pmid">18400922</pub-id>
                </element-citation>
              </ref>
              <ref id="B57-nutrients-15-04586">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cohen</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Botvinick</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Carter</surname>
                      <given-names>C.S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Anterior cingulate and prefrontal cortex: Who’s in control?</article-title>
                  <source>Nat. Neurosci.</source>
                  <year>2000</year>
                  <volume>3</volume>
                  <fpage>421</fpage>
                  <pub-id pub-id-type="doi">10.1038/74783</pub-id>
                  <?supplied-pmid 10769376?>
                  <pub-id pub-id-type="pmid">10769376</pub-id>
                </element-citation>
              </ref>
              <ref id="B58-nutrients-15-04586">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pizzagalli</surname>
                      <given-names>D.A.</given-names>
                    </name>
                    <name>
                      <surname>Peccoralo</surname>
                      <given-names>L.A.</given-names>
                    </name>
                    <name>
                      <surname>Davidson</surname>
                      <given-names>R.J.</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>J.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Resting anterior cingulate activity and abnormal responses to errors in subjects with elevated depressive symptoms: A 128-channel EEG study</article-title>
                  <source>Hum. Brain Mapp.</source>
                  <year>2006</year>
                  <volume>27</volume>
                  <fpage>185</fpage>
                  <lpage>201</lpage>
                  <pub-id pub-id-type="doi">10.1002/hbm.20172</pub-id>
                  <?supplied-pmid 16035102?>
                  <pub-id pub-id-type="pmid">16035102</pub-id>
                </element-citation>
              </ref>
              <ref id="B59-nutrients-15-04586">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Raichle</surname>
                      <given-names>M.E.</given-names>
                    </name>
                    <name>
                      <surname>MacLeod</surname>
                      <given-names>A.M.</given-names>
                    </name>
                    <name>
                      <surname>Snyder</surname>
                      <given-names>A.Z.</given-names>
                    </name>
                    <name>
                      <surname>Powers</surname>
                      <given-names>W.J.</given-names>
                    </name>
                    <name>
                      <surname>Gusnard</surname>
                      <given-names>D.A.</given-names>
                    </name>
                    <name>
                      <surname>Shulman</surname>
                      <given-names>G.L.</given-names>
                    </name>
                  </person-group>
                  <article-title>A default mode of brain function</article-title>
                  <source>Proc. Natl. Acad. Sci.</source>
                  <year>2001</year>
                  <volume>98</volume>
                  <fpage>676</fpage>
                  <lpage>682</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.98.2.676</pub-id>
                  <?supplied-pmid 11209064?>
                  <pub-id pub-id-type="pmid">11209064</pub-id>
                </element-citation>
              </ref>
              <ref id="B60-nutrients-15-04586">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vogt</surname>
                      <given-names>B.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pain and emotion interactions in subregions of the cingulate gyrus</article-title>
                  <source>Nat. Rev. Neurosci.</source>
                  <year>2005</year>
                  <volume>6</volume>
                  <fpage>533</fpage>
                  <lpage>544</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrn1704</pub-id>
                  <pub-id pub-id-type="pmid">15995724</pub-id>
                </element-citation>
              </ref>
              <ref id="B61-nutrients-15-04586">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Levar</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>van Leeuwen</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Puts</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Denys</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Van Wingen</surname>
                      <given-names>G.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>GABA concentrations in the anterior cingulate cortex are associated with fear network function and fear recovery in humans</article-title>
                  <source>Front. Hum. Neurosci.</source>
                  <year>2017</year>
                  <volume>11</volume>
                  <fpage>202</fpage>
                  <pub-id pub-id-type="doi">10.3389/fnhum.2017.00202</pub-id>
                  <pub-id pub-id-type="pmid">28496404</pub-id>
                </element-citation>
              </ref>
              <ref id="B62-nutrients-15-04586">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Makkar</surname>
                      <given-names>S.R.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>S.Q.</given-names>
                    </name>
                    <name>
                      <surname>Cranney</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory</article-title>
                  <source>Neuropsychopharmacology</source>
                  <year>2010</year>
                  <volume>35</volume>
                  <fpage>1625</fpage>
                  <lpage>1652</lpage>
                  <pub-id pub-id-type="doi">10.1038/npp.2010.53</pub-id>
                  <pub-id pub-id-type="pmid">20410874</pub-id>
                </element-citation>
              </ref>
              <ref id="B63-nutrients-15-04586">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Phelps</surname>
                      <given-names>E.A.</given-names>
                    </name>
                    <name>
                      <surname>Delgado</surname>
                      <given-names>M.R.</given-names>
                    </name>
                    <name>
                      <surname>Nearing</surname>
                      <given-names>K.I.</given-names>
                    </name>
                    <name>
                      <surname>LeDoux</surname>
                      <given-names>J.E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Extinction learning in humans: Role of the amygdala and vmPFC</article-title>
                  <source>Neuron</source>
                  <year>2004</year>
                  <volume>43</volume>
                  <fpage>897</fpage>
                  <lpage>905</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuron.2004.08.042</pub-id>
                  <pub-id pub-id-type="pmid">15363399</pub-id>
                </element-citation>
              </ref>
              <ref id="B64-nutrients-15-04586">
                <label>64.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shin</surname>
                      <given-names>L.M.</given-names>
                    </name>
                    <name>
                      <surname>Liberzon</surname>
                      <given-names>I.</given-names>
                    </name>
                  </person-group>
                  <article-title>The Neurocircuitry of Fear, Stress, and Anxiety Disorders</article-title>
                  <source>Neuropsychopharmacology</source>
                  <year>2010</year>
                  <volume>35</volume>
                  <fpage>169</fpage>
                  <lpage>191</lpage>
                  <pub-id pub-id-type="doi">10.1038/npp.2009.83</pub-id>
                  <?supplied-pmid 19625997?>
                  <pub-id pub-id-type="pmid">19625997</pub-id>
                </element-citation>
              </ref>
              <ref id="B65-nutrients-15-04586">
                <label>65.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>LaPorte</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Sarris</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Stough</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Scholey</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Neurocognitive effects of kava (<italic toggle="yes">Piper methysticum</italic>): A systematic review</article-title>
                  <source>Hum. Psychopharmacol.</source>
                  <year>2011</year>
                  <volume>26</volume>
                  <fpage>102</fpage>
                  <lpage>111</lpage>
                  <pub-id pub-id-type="doi">10.1002/hup.1180</pub-id>
                  <?supplied-pmid 21437989?>
                  <pub-id pub-id-type="pmid">21437989</pub-id>
                </element-citation>
              </ref>
              <ref id="B66-nutrients-15-04586">
                <label>66.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pittler</surname>
                      <given-names>M.H.</given-names>
                    </name>
                    <name>
                      <surname>Ernst</surname>
                      <given-names>E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kava extract for treating anxiety</article-title>
                  <source>Cochrane Database Syst. Rev.</source>
                  <year>2003</year>
                  <fpage>CD003383</fpage>
                  <pub-id pub-id-type="doi">10.1002/14651858.CD003383</pub-id>
                  <pub-id pub-id-type="pmid">12535473</pub-id>
                </element-citation>
              </ref>
              <ref id="B67-nutrients-15-04586">
                <label>67.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>Y.N.</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>N.N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Therapeutic potential of kava in the treatment of anxiety disorders</article-title>
                  <source>CNS Drugs</source>
                  <year>2002</year>
                  <volume>16</volume>
                  <fpage>731</fpage>
                  <lpage>743</lpage>
                  <pub-id pub-id-type="doi">10.2165/00023210-200216110-00002</pub-id>
                  <?supplied-pmid 12383029?>
                  <pub-id pub-id-type="pmid">12383029</pub-id>
                </element-citation>
              </ref>
              <ref id="B68-nutrients-15-04586">
                <label>68.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stevinson</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Huntley</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Ernst</surname>
                      <given-names>E.</given-names>
                    </name>
                  </person-group>
                  <article-title>A systematic review of the safety of kava extract in the treatment of anxiety</article-title>
                  <source>Drug Saf.</source>
                  <year>2002</year>
                  <volume>25</volume>
                  <fpage>251</fpage>
                  <lpage>261</lpage>
                  <pub-id pub-id-type="doi">10.2165/00002018-200225040-00003</pub-id>
                  <?supplied-pmid 11994028?>
                  <pub-id pub-id-type="pmid">11994028</pub-id>
                </element-citation>
              </ref>
              <ref id="B69-nutrients-15-04586">
                <label>69.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bensoussan</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Myers</surname>
                      <given-names>S.P.</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>O’Connor</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Naturopathic and Western herbal medicine practice in Australia—A workforce survey</article-title>
                  <source>Complement. Ther. Med.</source>
                  <year>2004</year>
                  <volume>12</volume>
                  <fpage>17</fpage>
                  <lpage>27</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ctim.2004.01.001</pub-id>
                  <?supplied-pmid 15130568?>
                  <pub-id pub-id-type="pmid">15130568</pub-id>
                </element-citation>
              </ref>
              <ref id="B70-nutrients-15-04586">
                <label>70.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lebot</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Merlin</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Lindstrom</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <source>Kava: The Pacific Drug</source>
                  <publisher-name>Yale University Press</publisher-name>
                  <publisher-loc>New Haven, CT, USA</publisher-loc>
                  <year>1992</year>
                </element-citation>
              </ref>
              <ref id="B71-nutrients-15-04586">
                <label>71.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pittler</surname>
                      <given-names>M.H.</given-names>
                    </name>
                    <name>
                      <surname>Ernst</surname>
                      <given-names>E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis</article-title>
                  <source>J. Clin. Psychopharmacol.</source>
                  <year>2000</year>
                  <volume>20</volume>
                  <fpage>84</fpage>
                  <lpage>89</lpage>
                  <pub-id pub-id-type="doi">10.1097/00004714-200002000-00014</pub-id>
                  <?supplied-pmid 10653213?>
                  <pub-id pub-id-type="pmid">10653213</pub-id>
                </element-citation>
              </ref>
              <ref id="B72-nutrients-15-04586">
                <label>72.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>Y.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kava: An overview</article-title>
                  <source>J. Ethnopharmacol.</source>
                  <year>1992</year>
                  <volume>37</volume>
                  <fpage>13</fpage>
                  <lpage>45</lpage>
                  <pub-id pub-id-type="doi">10.1016/0378-8741(92)90003-A</pub-id>
                  <pub-id pub-id-type="pmid">1453702</pub-id>
                </element-citation>
              </ref>
              <ref id="B73-nutrients-15-04586">
                <label>73.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tzeng</surname>
                      <given-names>Y.M.</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>M.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Neuroprotective properties of kavalactones</article-title>
                  <source>Neural Regen. Res.</source>
                  <year>2015</year>
                  <volume>10</volume>
                  <fpage>875</fpage>
                  <lpage>877</lpage>
                  <pub-id pub-id-type="pmid">26199594</pub-id>
                </element-citation>
              </ref>
              <ref id="B74-nutrients-15-04586">
                <label>74.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bilia</surname>
                      <given-names>A.R.</given-names>
                    </name>
                    <name>
                      <surname>Bergonzi</surname>
                      <given-names>M.C.</given-names>
                    </name>
                    <name>
                      <surname>Lazari</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Vincieri</surname>
                      <given-names>F.F.</given-names>
                    </name>
                  </person-group>
                  <article-title>Characterization of commercial kava-kava herbal drug and herbal drug preparations by means of nuclear magnetic resonance spectroscopy</article-title>
                  <source>J. Agric. Food Chem.</source>
                  <year>2002</year>
                  <volume>50</volume>
                  <fpage>5016</fpage>
                  <lpage>5025</lpage>
                  <pub-id pub-id-type="doi">10.1021/jf020049j</pub-id>
                  <pub-id pub-id-type="pmid">12188601</pub-id>
                </element-citation>
              </ref>
              <ref id="B75-nutrients-15-04586">
                <label>75.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chua</surname>
                      <given-names>H.C.</given-names>
                    </name>
                    <name>
                      <surname>Christensen</surname>
                      <given-names>E.T.</given-names>
                    </name>
                    <name>
                      <surname>Hoestgaard-Jensen</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Hartiadi</surname>
                      <given-names>L.Y.</given-names>
                    </name>
                    <name>
                      <surname>Ramzan</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Jensen</surname>
                      <given-names>A.A.</given-names>
                    </name>
                    <name>
                      <surname>Chebib</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism</article-title>
                  <source>PLoS ONE</source>
                  <year>2016</year>
                  <volume>11</volume>
                  <elocation-id>e0157700</elocation-id>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0157700</pub-id>
                  <pub-id pub-id-type="pmid">27332705</pub-id>
                </element-citation>
              </ref>
              <ref id="B76-nutrients-15-04586">
                <label>76.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Duffield</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Jamieson</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Lidgard</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Duffield</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Bourne</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Identification of some human urinary metabolites of the intoxicating beverage kava</article-title>
                  <source>J. Chromatogr. A</source>
                  <year>1989</year>
                  <volume>475</volume>
                  <fpage>273</fpage>
                  <lpage>281</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0021-9673(01)89682-5</pub-id>
                  <?supplied-pmid 2777959?>
                  <pub-id pub-id-type="pmid">2777959</pub-id>
                </element-citation>
              </ref>
              <ref id="B77-nutrients-15-04586">
                <label>77.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meyer</surname>
                      <given-names>H.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacology of kava</article-title>
                  <source>Ethnopharmacologic Search for Psychoactive Drugs</source>
                  <publisher-name>Raven Press</publisher-name>
                  <publisher-loc>New York, NY, USA</publisher-loc>
                  <year>1979</year>
                </element-citation>
              </ref>
              <ref id="B78-nutrients-15-04586">
                <label>78.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boonen</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Haberlein</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Influence of genuine kavapyrone enantiomers on the GABA-A binding site</article-title>
                  <source>Planta Med.</source>
                  <year>1998</year>
                  <volume>64</volume>
                  <fpage>504</fpage>
                  <lpage>506</lpage>
                  <pub-id pub-id-type="doi">10.1055/s-2006-957502</pub-id>
                  <?supplied-pmid 9776662?>
                  <pub-id pub-id-type="pmid">9776662</pub-id>
                </element-citation>
              </ref>
              <ref id="B79-nutrients-15-04586">
                <label>79.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>L.P.</given-names>
                    </name>
                    <name>
                      <surname>Drew</surname>
                      <given-names>C.A.</given-names>
                    </name>
                    <name>
                      <surname>Duffield</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Johnston</surname>
                      <given-names>G.A.</given-names>
                    </name>
                    <name>
                      <surname>Jamieson</surname>
                      <given-names>D.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kava pyrones and resin: Studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain</article-title>
                  <source>Pharmacol. Toxicol.</source>
                  <year>1992</year>
                  <volume>71</volume>
                  <fpage>120</fpage>
                  <lpage>126</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1600-0773.1992.tb00530.x</pub-id>
                  <pub-id pub-id-type="pmid">1332016</pub-id>
                </element-citation>
              </ref>
              <ref id="B80-nutrients-15-04586">
                <label>80.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yuan</surname>
                      <given-names>C.S.</given-names>
                    </name>
                    <name>
                      <surname>Dey</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Mehendale</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Xie</surname>
                      <given-names>J.T.</given-names>
                    </name>
                    <name>
                      <surname>Aung</surname>
                      <given-names>H.H.</given-names>
                    </name>
                    <name>
                      <surname>Ang-Lee</surname>
                      <given-names>M.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation</article-title>
                  <source>Planta Medica</source>
                  <year>2002</year>
                  <volume>68</volume>
                  <fpage>1092</fpage>
                  <lpage>1096</lpage>
                  <pub-id pub-id-type="doi">10.1055/s-2002-36338</pub-id>
                  <?supplied-pmid 12494336?>
                  <pub-id pub-id-type="pmid">12494336</pub-id>
                </element-citation>
              </ref>
              <ref id="B81-nutrients-15-04586">
                <label>81.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boonen</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Ferger</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Kuschinsky</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Haberlein</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>In Vivo effects of the kavapyrones (+)-dihydromethysticin (+/−)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions</article-title>
                  <source>Planta Medica</source>
                  <year>1998</year>
                  <volume>64</volume>
                  <fpage>507</fpage>
                  <lpage>510</lpage>
                  <pub-id pub-id-type="doi">10.1055/s-2006-957503</pub-id>
                  <?supplied-pmid 9741294?>
                  <pub-id pub-id-type="pmid">9741294</pub-id>
                </element-citation>
              </ref>
              <ref id="B82-nutrients-15-04586">
                <label>82.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gleitz</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Beile</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Peters</surname>
                      <given-names>T.</given-names>
                    </name>
                  </person-group>
                  <article-title>(+/−)-Kavain inhibits veratridine-activated voltage dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex</article-title>
                  <source>Neuropharmacology</source>
                  <year>1995</year>
                  <volume>34</volume>
                  <fpage>1133</fpage>
                  <lpage>1138</lpage>
                  <pub-id pub-id-type="doi">10.1016/0028-3908(95)00090-S</pub-id>
                  <?supplied-pmid 8532183?>
                  <pub-id pub-id-type="pmid">8532183</pub-id>
                </element-citation>
              </ref>
              <ref id="B83-nutrients-15-04586">
                <label>83.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jamieson</surname>
                      <given-names>D.D.</given-names>
                    </name>
                    <name>
                      <surname>Duffield</surname>
                      <given-names>P.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Positive interaction of ethanol and kava resin in mice</article-title>
                  <source>Clin. Exp. Pharmacol. Physiol.</source>
                  <year>1990</year>
                  <volume>17</volume>
                  <fpage>509</fpage>
                  <lpage>514</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1440-1681.1990.tb01350.x</pub-id>
                  <pub-id pub-id-type="pmid">2401104</pub-id>
                </element-citation>
              </ref>
              <ref id="B84-nutrients-15-04586">
                <label>84.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lehmann</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Klieser</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Klimke</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Krach</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Spatz</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>The efficacy of Cavain in patients suffering from anxiety</article-title>
                  <source>Pharmacopsychiatry</source>
                  <year>1989</year>
                  <volume>22</volume>
                  <fpage>258</fpage>
                  <lpage>262</lpage>
                  <pub-id pub-id-type="doi">10.1055/s-2007-1014611</pub-id>
                  <pub-id pub-id-type="pmid">2575765</pub-id>
                </element-citation>
              </ref>
              <ref id="B85-nutrients-15-04586">
                <label>85.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sarris</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Kavanagh</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Adams</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Bone</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kava Anxiety Depression Spectrum Study (KADSS): A mixed methods RCT using an aqueous extract of <italic toggle="yes">Piper methysticum</italic></article-title>
                  <source>Complement. Ther. Med.</source>
                  <year>2009</year>
                  <volume>17</volume>
                  <fpage>176</fpage>
                  <lpage>178</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ctim.2009.01.001</pub-id>
                  <pub-id pub-id-type="pmid">19398072</pub-id>
                </element-citation>
              </ref>
              <ref id="B86-nutrients-15-04586">
                <label>86.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saletu</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Grünberger</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Linzmayer</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Anderer</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>EEG-Brain mapping, psychometric and psychophysiological studies on central effects of kavain—A kava plant derivative</article-title>
                  <source>Hum. Psychopharmacol.: Clin. Exp.</source>
                  <year>1989</year>
                  <volume>4</volume>
                  <fpage>169</fpage>
                  <lpage>190</lpage>
                  <pub-id pub-id-type="doi">10.1002/hup.470040304</pub-id>
                </element-citation>
              </ref>
              <ref id="B87-nutrients-15-04586">
                <label>87.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Savage</surname>
                      <given-names>K.M.</given-names>
                    </name>
                    <name>
                      <surname>Stough</surname>
                      <given-names>C.K.</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>G.J.</given-names>
                    </name>
                    <name>
                      <surname>Scholey</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Bousman</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Sarris</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kava for the treatment of generalised anxiety disorder (K-GAD): Study protocol for a randomised controlled trial</article-title>
                  <source>Trials</source>
                  <year>2015</year>
                  <volume>16</volume>
                  <fpage>493</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13063-015-0986-5</pub-id>
                  <pub-id pub-id-type="pmid">26527536</pub-id>
                </element-citation>
              </ref>
              <ref id="B88-nutrients-15-04586">
                <label>88.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sarris</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>G.J.</given-names>
                    </name>
                    <name>
                      <surname>Bousman</surname>
                      <given-names>C.A.</given-names>
                    </name>
                    <name>
                      <surname>Cribb</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Savage</surname>
                      <given-names>K.M.</given-names>
                    </name>
                    <name>
                      <surname>Holmes</surname>
                      <given-names>O.</given-names>
                    </name>
                    <name>
                      <surname>Stough</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study</article-title>
                  <source>Aust. New Zealand J. Psychiatry</source>
                  <year>2020</year>
                  <volume>54</volume>
                  <fpage>288</fpage>
                  <lpage>297</lpage>
                  <pub-id pub-id-type="doi">10.1177/0004867419891246</pub-id>
                  <?supplied-pmid 31813230?>
                  <pub-id pub-id-type="pmid">31813230</pub-id>
                </element-citation>
              </ref>
              <ref id="B89-nutrients-15-04586">
                <label>89.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Faul</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Erdfelder</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Lang</surname>
                      <given-names>A.G.</given-names>
                    </name>
                    <name>
                      <surname>Buchner</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>G* Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title>
                  <source>Behav. Res. Methods</source>
                  <year>2007</year>
                  <volume>39</volume>
                  <fpage>175</fpage>
                  <lpage>191</lpage>
                  <pub-id pub-id-type="doi">10.3758/BF03193146</pub-id>
                  <?supplied-pmid 17695343?>
                  <pub-id pub-id-type="pmid">17695343</pub-id>
                </element-citation>
              </ref>
              <ref id="B90-nutrients-15-04586">
                <label>90.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sheehan</surname>
                      <given-names>D.V.</given-names>
                    </name>
                    <name>
                      <surname>Lecrubier</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Sheehan</surname>
                      <given-names>K.H.</given-names>
                    </name>
                    <name>
                      <surname>Amorim</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Janavs</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Weiller</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Dunbar</surname>
                      <given-names>G.C.</given-names>
                    </name>
                  </person-group>
                  <article-title>The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title>
                  <source>J. Clin. Psychiatry</source>
                  <year>1998</year>
                  <volume>59</volume>
                  <fpage>22</fpage>
                  <lpage>33</lpage>
                  <?supplied-pmid 9881538?>
                  <pub-id pub-id-type="pmid">9881538</pub-id>
                </element-citation>
              </ref>
              <ref id="B91-nutrients-15-04586">
                <label>91.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>American Psychiatric Association</collab>
                  </person-group>
                  <source>Diagnostic and Statistical Manual of Mental Disorders</source>
                  <edition>5th ed.</edition>
                  <publisher-name>American Psychiatric Press</publisher-name>
                  <publisher-loc>Washington, DC, USA</publisher-loc>
                  <year>2013</year>
                </element-citation>
              </ref>
              <ref id="B92-nutrients-15-04586">
                <label>92.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>The assessment of anxiety states by rating</article-title>
                  <source>Br. J. Med. Psychol.</source>
                  <year>1959</year>
                  <volume>32</volume>
                  <fpage>50</fpage>
                  <lpage>55</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.2044-8341.1959.tb00467.x</pub-id>
                  <?supplied-pmid 13638508?>
                  <pub-id pub-id-type="pmid">13638508</pub-id>
                </element-citation>
              </ref>
              <ref id="B93-nutrients-15-04586">
                <label>93.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Montgomery</surname>
                      <given-names>S.A.</given-names>
                    </name>
                    <name>
                      <surname>Åsberg</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>A new depression scale designed to be sensitive to change</article-title>
                  <source>Br. J. Psychiatry</source>
                  <year>1979</year>
                  <volume>134</volume>
                  <fpage>382</fpage>
                  <lpage>389</lpage>
                  <pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id>
                  <?supplied-pmid 444788?>
                  <pub-id pub-id-type="pmid">444788</pub-id>
                </element-citation>
              </ref>
              <ref id="B94-nutrients-15-04586">
                <label>94.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Williams</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Kobak</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <source>Structured Interview Guide for the Montgomery Asberg Depression Rating Scale (SIG-MA)</source>
                  <publisher-name>Biometrics Research Department</publisher-name>
                  <publisher-loc>New York, NY, USA</publisher-loc>
                  <year>1996</year>
                </element-citation>
              </ref>
              <ref id="B95-nutrients-15-04586">
                <label>95.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Noyes</surname>
                      <given-names>R.</given-names>
                      <suffix>Jr.</suffix>
                    </name>
                  </person-group>
                  <article-title>Comorbidity in generalized anxiety disorder</article-title>
                  <source>Psychiatr. Clin. North Am.</source>
                  <year>2001</year>
                  <volume>24</volume>
                  <fpage>41</fpage>
                  <lpage>55</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0193-953X(05)70205-7</pub-id>
                  <?supplied-pmid 11225508?>
                  <pub-id pub-id-type="pmid">11225508</pub-id>
                </element-citation>
              </ref>
              <ref id="B96-nutrients-15-04586">
                <label>96.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nutt</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Ballenger</surname>
                      <given-names>J.C.</given-names>
                    </name>
                    <name>
                      <surname>Sheehan</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Wittchen</surname>
                      <given-names>H.-U.</given-names>
                    </name>
                  </person-group>
                  <article-title>Generalized anxiety disorder: Comorbidity, comparative biology and treatment</article-title>
                  <source>Int. J. Neuropsychopharmacol.</source>
                  <year>2002</year>
                  <volume>5</volume>
                  <fpage>315</fpage>
                  <lpage>325</lpage>
                  <pub-id pub-id-type="doi">10.1017/S1461145702003048</pub-id>
                  <?supplied-pmid 12466031?>
                  <pub-id pub-id-type="pmid">12466031</pub-id>
                </element-citation>
              </ref>
              <ref id="B97-nutrients-15-04586">
                <label>97.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shear</surname>
                      <given-names>M.K.</given-names>
                    </name>
                    <name>
                      <surname>Vander Bilt</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Rucci</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Endicott</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Lydiard</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Otto</surname>
                      <given-names>M.W.</given-names>
                    </name>
                    <name>
                      <surname>Frank</surname>
                      <given-names>D.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A)</article-title>
                  <source>Depress. Anxiety</source>
                  <year>2001</year>
                  <volume>13</volume>
                  <fpage>166</fpage>
                  <lpage>178</lpage>
                  <pub-id pub-id-type="doi">10.1002/da.1033</pub-id>
                  <pub-id pub-id-type="pmid">11413563</pub-id>
                </element-citation>
              </ref>
              <ref id="B98-nutrients-15-04586">
                <label>98.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mescher</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Merkle</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Kirsch</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Garwood</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Gruetter</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Simultaneous in vivo spectral editing and water suppression</article-title>
                  <source>NMR Biomed.</source>
                  <year>1998</year>
                  <volume>11</volume>
                  <fpage>266</fpage>
                  <lpage>272</lpage>
                  <pub-id pub-id-type="doi">10.1002/(SICI)1099-1492(199810)11:6&lt;266::AID-NBM530&gt;3.0.CO;2-J</pub-id>
                  <pub-id pub-id-type="pmid">9802468</pub-id>
                </element-citation>
              </ref>
              <ref id="B99-nutrients-15-04586">
                <label>99.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rorden</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Brett</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Stereotaxic display of brain lesions</article-title>
                  <source>Behav. Neurol.</source>
                  <year>2000</year>
                  <volume>12</volume>
                  <fpage>191</fpage>
                  <lpage>200</lpage>
                  <pub-id pub-id-type="doi">10.1155/2000/421719</pub-id>
                  <?supplied-pmid 11568431?>
                  <pub-id pub-id-type="pmid">11568431</pub-id>
                </element-citation>
              </ref>
              <ref id="B100-nutrients-15-04586">
                <label>100.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Edden</surname>
                      <given-names>R.A.</given-names>
                    </name>
                    <name>
                      <surname>Puts</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Harris</surname>
                      <given-names>A.D.</given-names>
                    </name>
                    <name>
                      <surname>Barker</surname>
                      <given-names>P.B.</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>C.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Gannet: A batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra</article-title>
                  <source>J. Magn. Reson. Imaging</source>
                  <year>2014</year>
                  <volume>40</volume>
                  <fpage>1445</fpage>
                  <lpage>1452</lpage>
                  <pub-id pub-id-type="doi">10.1002/jmri.24478</pub-id>
                  <?supplied-pmid 25548816?>
                  <pub-id pub-id-type="pmid">25548816</pub-id>
                </element-citation>
              </ref>
              <ref id="B101-nutrients-15-04586">
                <label>101.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Provencher</surname>
                      <given-names>S.W.</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimation of metabolite concentrations from localized in vivo proton NMR spectra</article-title>
                  <source>Magn. Reson. Med.</source>
                  <year>1993</year>
                  <volume>30</volume>
                  <fpage>672</fpage>
                  <lpage>679</lpage>
                  <pub-id pub-id-type="doi">10.1002/mrm.1910300604</pub-id>
                  <?supplied-pmid 8139448?>
                  <pub-id pub-id-type="pmid">8139448</pub-id>
                </element-citation>
              </ref>
              <ref id="B102-nutrients-15-04586">
                <label>102.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Provencher</surname>
                      <given-names>S.W.</given-names>
                    </name>
                  </person-group>
                  <article-title>Automatic quantitation of localized in vivo 1H spectra with LCModel</article-title>
                  <source>NMR Biomed.</source>
                  <year>2001</year>
                  <volume>14</volume>
                  <fpage>260</fpage>
                  <lpage>264</lpage>
                  <pub-id pub-id-type="doi">10.1002/nbm.698</pub-id>
                  <?supplied-pmid 11410943?>
                  <pub-id pub-id-type="pmid">11410943</pub-id>
                </element-citation>
              </ref>
              <ref id="B103-nutrients-15-04586">
                <label>103.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ganji</surname>
                      <given-names>S.K.</given-names>
                    </name>
                    <name>
                      <surname>An</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Banerjee</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Madan</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Hulsey</surname>
                      <given-names>K.M.</given-names>
                    </name>
                    <name>
                      <surname>Choi</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Measurement of regional variation of GABA in the human brain by optimized point-resolved spectroscopy at 7 T in vivo</article-title>
                  <source>NMR Biomed.</source>
                  <year>2014</year>
                  <volume>27</volume>
                  <fpage>1167</fpage>
                  <lpage>1175</lpage>
                  <pub-id pub-id-type="doi">10.1002/nbm.3170</pub-id>
                  <?supplied-pmid 25088346?>
                  <pub-id pub-id-type="pmid">25088346</pub-id>
                </element-citation>
              </ref>
              <ref id="B104-nutrients-15-04586">
                <label>104.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harris</surname>
                      <given-names>A.D.</given-names>
                    </name>
                    <name>
                      <surname>Puts</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Edden</surname>
                      <given-names>R.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Tissue correction for GABA-edited MRS: Considerations of voxel composition, tissue segmentation, and tissue relaxations</article-title>
                  <source>J. Magn. Reson. Imaging</source>
                  <year>2015</year>
                  <volume>42</volume>
                  <fpage>1431</fpage>
                  <lpage>1440</lpage>
                  <pub-id pub-id-type="doi">10.1002/jmri.24903</pub-id>
                  <?supplied-pmid 26172043?>
                  <pub-id pub-id-type="pmid">26172043</pub-id>
                </element-citation>
              </ref>
              <ref id="B105-nutrients-15-04586">
                <label>105.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kreis</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Ernst</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Ross</surname>
                      <given-names>B.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy</article-title>
                  <source>Magn. Reson. Med.</source>
                  <year>1993</year>
                  <volume>30</volume>
                  <fpage>424</fpage>
                  <lpage>437</lpage>
                  <pub-id pub-id-type="doi">10.1002/mrm.1910300405</pub-id>
                  <pub-id pub-id-type="pmid">8255190</pub-id>
                </element-citation>
              </ref>
              <ref id="B106-nutrients-15-04586">
                <label>106.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mikkelsen</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>K.D.</given-names>
                    </name>
                    <name>
                      <surname>Brealy</surname>
                      <given-names>J.A.</given-names>
                    </name>
                    <name>
                      <surname>Linden</surname>
                      <given-names>D.E.</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>C.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantification of γ-aminobutyric acid (GABA) in 1H MRS volumes composed heterogeneously of grey and white matter</article-title>
                  <source>NMR Biomed.</source>
                  <year>2016</year>
                  <volume>29</volume>
                  <fpage>1644</fpage>
                  <lpage>1655</lpage>
                  <pub-id pub-id-type="doi">10.1002/nbm.3622</pub-id>
                  <pub-id pub-id-type="pmid">27687518</pub-id>
                </element-citation>
              </ref>
              <ref id="B107-nutrients-15-04586">
                <label>107.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirkovski</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Suo</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Enticott</surname>
                      <given-names>P.G.</given-names>
                    </name>
                    <name>
                      <surname>Yucel</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Fitzgerald</surname>
                      <given-names>P.B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Short communication: Sex-linked differences in gamma-aminobutyric acid (GABA) are related to social functioning in autism spectrum disorder</article-title>
                  <source>Psychiatry. Res. Neuroimaging</source>
                  <year>2018</year>
                  <volume>274</volume>
                  <fpage>19</fpage>
                  <lpage>22</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pscychresns.2018.02.004</pub-id>
                  <pub-id pub-id-type="pmid">29500101</pub-id>
                </element-citation>
              </ref>
              <ref id="B108-nutrients-15-04586">
                <label>108.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sarris</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>LaPorte</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Schweitzer</surname>
                      <given-names>I.</given-names>
                    </name>
                  </person-group>
                  <article-title>Kava: A comprehensive review of efficacy, safety, and psychopharmacology</article-title>
                  <source>Aust. N. Z. J. Psychiatry</source>
                  <year>2011</year>
                  <volume>45</volume>
                  <fpage>27</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="doi">10.3109/00048674.2010.522554</pub-id>
                  <?supplied-pmid 21073405?>
                  <pub-id pub-id-type="pmid">21073405</pub-id>
                </element-citation>
              </ref>
              <ref id="B109-nutrients-15-04586">
                <label>109.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Witte</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Loew</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Gaus</surname>
                      <given-names>W.</given-names>
                    </name>
                  </person-group>
                  <article-title>Meta-analysis of the efficacy of the acetonic kava-kava extract WS<sup>®</sup> 1490 in patients with non-psychotic anxiety disorders</article-title>
                  <source>Phytother. Res. Int. J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv.</source>
                  <year>2005</year>
                  <volume>19</volume>
                  <fpage>183</fpage>
                  <lpage>188</lpage>
                  <pub-id pub-id-type="doi">10.1002/ptr.1609</pub-id>
                  <?supplied-pmid 15934028?>
                  <pub-id pub-id-type="pmid">15934028</pub-id>
                </element-citation>
              </ref>
              <ref id="B110-nutrients-15-04586">
                <label>110.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krum</surname>
                      <given-names>B.N.</given-names>
                    </name>
                    <name>
                      <surname>de Freitas</surname>
                      <given-names>C.M.</given-names>
                    </name>
                    <name>
                      <surname>Busanello</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Schaffer</surname>
                      <given-names>L.F.</given-names>
                    </name>
                    <name>
                      <surname>Fachinetto</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Ex vivo and in vitro inhibitory potential of Kava extract on monoamine oxidase B activity in mice</article-title>
                  <source>J. Tradit. Complement. Med.</source>
                  <year>2022</year>
                  <volume>12</volume>
                  <fpage>115</fpage>
                  <lpage>122</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jtcme.2021.07.002</pub-id>
                  <?supplied-pmid 35528470?>
                  <pub-id pub-id-type="pmid">35528470</pub-id>
                </element-citation>
              </ref>
              <ref id="B111-nutrients-15-04586">
                <label>111.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mikkelsen</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Barker</surname>
                      <given-names>P.B.</given-names>
                    </name>
                    <name>
                      <surname>Bhattacharyya</surname>
                      <given-names>P.K.</given-names>
                    </name>
                    <name>
                      <surname>Brix</surname>
                      <given-names>M.K.</given-names>
                    </name>
                    <name>
                      <surname>Buur</surname>
                      <given-names>P.F.</given-names>
                    </name>
                    <name>
                      <surname>Cecil</surname>
                      <given-names>K.M.</given-names>
                    </name>
                    <name>
                      <surname>Edden</surname>
                      <given-names>R.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Big GABA: Edited MR spectroscopy at 24 research sites</article-title>
                  <source>Neuroimage</source>
                  <year>2017</year>
                  <volume>159</volume>
                  <fpage>32</fpage>
                  <lpage>45</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.07.021</pub-id>
                  <?supplied-pmid 28716717?>
                  <pub-id pub-id-type="pmid">28716717</pub-id>
                </element-citation>
              </ref>
              <ref id="B112-nutrients-15-04586">
                <label>112.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mullins</surname>
                      <given-names>P.G.</given-names>
                    </name>
                    <name>
                      <surname>McGonigle</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>O’Gorman</surname>
                      <given-names>R.L.</given-names>
                    </name>
                    <name>
                      <surname>Puts</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Vidyasagar</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Evans</surname>
                      <given-names>C.J.</given-names>
                    </name>
                    <name>
                      <surname>Edden</surname>
                      <given-names>R.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA</article-title>
                  <source>Neuroimage</source>
                  <year>2014</year>
                  <volume>86</volume>
                  <fpage>43</fpage>
                  <lpage>52</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.12.004</pub-id>
                  <?supplied-pmid 23246994?>
                  <pub-id pub-id-type="pmid">23246994</pub-id>
                </element-citation>
              </ref>
              <ref id="B113-nutrients-15-04586">
                <label>113.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stagg</surname>
                      <given-names>C.J.</given-names>
                    </name>
                    <name>
                      <surname>Bachtiar</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Johansen-Berg</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>What are we measuring with GABA magnetic resonance spectroscopy?</article-title>
                  <source>Commun. Integr. Biol.</source>
                  <year>2011</year>
                  <volume>4</volume>
                  <fpage>573</fpage>
                  <lpage>575</lpage>
                  <pub-id pub-id-type="doi">10.4161/cib.16213</pub-id>
                  <?supplied-pmid 22046466?>
                  <pub-id pub-id-type="pmid">22046466</pub-id>
                </element-citation>
              </ref>
              <ref id="B114-nutrients-15-04586">
                <label>114.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Insel</surname>
                      <given-names>T.R.</given-names>
                    </name>
                  </person-group>
                  <article-title>The NIMH Research Domain Criteria (RDoC) Project: Precision medicine for psychiatry</article-title>
                  <source>Am. J. Psychiatry</source>
                  <year>2014</year>
                  <volume>171</volume>
                  <fpage>395</fpage>
                  <lpage>397</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.ajp.2014.14020138</pub-id>
                  <pub-id pub-id-type="pmid">24687194</pub-id>
                </element-citation>
              </ref>
              <ref id="B115-nutrients-15-04586">
                <label>115.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Williams</surname>
                      <given-names>L.M.</given-names>
                    </name>
                    <name>
                      <surname>Goldstein-Piekarski</surname>
                      <given-names>A.N.</given-names>
                    </name>
                    <name>
                      <surname>Chowdhry</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Grisanzio</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <name>
                      <surname>Haug</surname>
                      <given-names>N.A.</given-names>
                    </name>
                    <name>
                      <surname>Samara</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Yesavage</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: Protocol for the baseline-follow up Research domain criteria Anxiety and Depression (“RAD”) project</article-title>
                  <source>BMC Psychiatry</source>
                  <year>2016</year>
                  <volume>16</volume>
                  <elocation-id>68</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/s12888-016-0771-3</pub-id>
                  <pub-id pub-id-type="pmid">26980207</pub-id>
                </element-citation>
              </ref>
              <ref id="B116-nutrients-15-04586">
                <label>116.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McNaughton</surname>
                      <given-names>N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Development of a theoretically-derived human anxiety syndrome biomarker</article-title>
                  <source>Transl. Neurosci.</source>
                  <year>2014</year>
                  <volume>5</volume>
                  <fpage>137</fpage>
                  <lpage>146</lpage>
                  <pub-id pub-id-type="doi">10.2478/s13380-014-0220-z</pub-id>
                </element-citation>
              </ref>
              <ref id="B117-nutrients-15-04586">
                <label>117.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sanislow</surname>
                      <given-names>C.A.</given-names>
                    </name>
                    <name>
                      <surname>Pine</surname>
                      <given-names>D.S.</given-names>
                    </name>
                    <name>
                      <surname>Quinn</surname>
                      <given-names>K.J.</given-names>
                    </name>
                    <name>
                      <surname>Kozak</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Garvey</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Heinssen</surname>
                      <given-names>R.K.</given-names>
                    </name>
                    <name>
                      <surname>Cuthbert</surname>
                      <given-names>B.N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Developing constructs for psychopathology research: Research domain criteria</article-title>
                  <source>J. Abnorm. Psychol.</source>
                  <year>2010</year>
                  <volume>119</volume>
                  <fpage>631</fpage>
                  <lpage>639</lpage>
                  <pub-id pub-id-type="doi">10.1037/a0020909</pub-id>
                  <pub-id pub-id-type="pmid">20939653</pub-id>
                </element-citation>
              </ref>
              <ref id="B118-nutrients-15-04586">
                <label>118.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cuthbert</surname>
                      <given-names>B.N.</given-names>
                    </name>
                    <name>
                      <surname>Insel</surname>
                      <given-names>T.R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Toward the future of psychiatric diagnosis: The seven pillars of RDoC</article-title>
                  <source>BMC Med.</source>
                  <year>2013</year>
                  <volume>11</volume>
                  <elocation-id>126</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/1741-7015-11-126</pub-id>
                  <pub-id pub-id-type="pmid">23672542</pub-id>
                </element-citation>
              </ref>
              <ref id="B119-nutrients-15-04586">
                <label>119.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fernandes</surname>
                      <given-names>B.S.</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>L.M.</given-names>
                    </name>
                    <name>
                      <surname>Steiner</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Leboyer</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Carvalho</surname>
                      <given-names>A.F.</given-names>
                    </name>
                    <name>
                      <surname>Berk</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>The new field of ‘precision psychiatry’</article-title>
                  <source>BMC Med.</source>
                  <year>2017</year>
                  <volume>15</volume>
                  <elocation-id>80</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/s12916-017-0849-x</pub-id>
                  <pub-id pub-id-type="pmid">28403846</pub-id>
                </element-citation>
              </ref>
              <ref id="B120-nutrients-15-04586">
                <label>120.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Rose</surname>
                      <given-names>N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Biomarkers in psychiatry</article-title>
                  <source>Nature</source>
                  <year>2009</year>
                  <volume>460</volume>
                  <fpage>202</fpage>
                  <lpage>207</lpage>
                  <pub-id pub-id-type="doi">10.1038/460202a</pub-id>
                  <pub-id pub-id-type="pmid">19587761</pub-id>
                </element-citation>
              </ref>
              <ref id="B121-nutrients-15-04586">
                <label>121.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lueken</surname>
                      <given-names>U.</given-names>
                    </name>
                    <name>
                      <surname>Zierhut</surname>
                      <given-names>K.C.</given-names>
                    </name>
                    <name>
                      <surname>Hahn</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Straube</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Kircher</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Reif</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Domschke</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Neurobiological markers predicting treatment response in anxiety disorders: A systematic review and implications for clinical application</article-title>
                  <source>Neurosci. Biobehav. Rev.</source>
                  <year>2016</year>
                  <volume>66</volume>
                  <fpage>143</fpage>
                  <lpage>162</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.04.005</pub-id>
                  <pub-id pub-id-type="pmid">27168345</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="nutrients-15-04586-f001">
              <label>Figure 1</label>
              <caption>
                <p>An example of tissue segmentation at individual space to segment grey matter (GM), white matter (WM), and CSF. The volumetric proportion (percentage) of each tissue type within the MRS voxel was further calculated for a partial volume correction check.</p>
              </caption>
              <graphic xlink:href="nutrients-15-04586-g001" position="float"/>
            </fig>
            <fig position="float" id="nutrients-15-04586-f002">
              <label>Figure 2</label>
              <caption>
                <p>The averaged voxel location for MRS for all scans transferred into MNI space; the target region is the dorsal subregion of the anterior cingulate cortex (dACC).</p>
              </caption>
              <graphic xlink:href="nutrients-15-04586-g002" position="float"/>
            </fig>
            <fig position="float" id="nutrients-15-04586-f003">
              <label>Figure 3</label>
              <caption>
                <p>CONSORT diagram for intervention.</p>
              </caption>
              <graphic xlink:href="nutrients-15-04586-g003" position="float"/>
            </fig>
            <fig position="float" id="nutrients-15-04586-f004">
              <label>Figure 4</label>
              <caption>
                <p>LCModel GABA means per group, baseline (T1) to eight weeks (T2).</p>
              </caption>
              <graphic xlink:href="nutrients-15-04586-g004" position="float"/>
            </fig>
            <table-wrap position="float" id="nutrients-15-04586-t001">
              <object-id pub-id-type="pii">nutrients-15-04586-t001_Table 1</object-id>
              <label>Table 1</label>
              <caption>
                <p>Demographics and GABA data for treatment groups and time points.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Demographics <break/><italic toggle="yes">Mean (S.D.), n or % where relevant</italic></th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Baseline <break/>Whole Group</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Baseline Placebo</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Baseline Kava</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tmt <break/><italic toggle="yes">p</italic>-Value *</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Week 8<break/>Whole Group</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Week 8 Placebo</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Week 8<break/>Kava</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Participants (n)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (9 male)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (11 male)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.653</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.16 (13.09)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.06 (11.31)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.25 (14.73)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.965</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Education (years) </td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.65 (3.91)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.59 (4.70)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.85 (2.98)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.181</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
                      <italic toggle="yes">Psychiatric</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comorbid condition</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.110</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comorbid: SAD </td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.395</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comorbid: PD </td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.034 *</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comorbid: AGO</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.324</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comorbid: PTSD</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.460</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comorbid: MDD </td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.581</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HAM-A <sup>a</sup></td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.05 (3.60)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.29 (4.19)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.85 (3.10)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.714</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.55 (5.69)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.00 (6.20)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.82 (5.17)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MADRS <sup>b</sup></td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.59 (2.99)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.00 (2.91)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.25 (3.09)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.456</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.38 (5.30)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.67 (4.82)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.17 (5.84)</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
                      <italic toggle="yes">Medical</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medications</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.357</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Supplements</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.103</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
                      <italic toggle="yes">Substance</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caffeine (mg/daily)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">135.54 (127.64)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">156.47 (132.96)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">117.75 (123.51)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.365</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.55 (83.71)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.27 (68.93)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.50 (98.52)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol (SD/weekly)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.86 (3.08)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.88 (2.02)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.70 (3.60)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.073</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.10 (3.65)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.67 (1.50)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.09 (3.73)</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
                      <italic toggle="yes">Volumetric</italic>
                    </td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dACC GM (%, mm<sup>3</sup>)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.29 (13.20)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.41 (12.22)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.05 (14.25)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.712</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.35 (12.33)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.11 (15.89)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.64 (6.45)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dACC WM (%, mm<sup>3</sup>)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.48 (11.46)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.58 (11.86)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.55 (11.34)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.597</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.40 (10.78)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.67 (13.90)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.91 (6.02)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dACC CSF (%, mm<sup>3</sup>)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.57 (5.04)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.53 (3.93)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.47 (5.77)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.249</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.01 (6.18)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.44 (4.56)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.84 (7.26)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
                      <italic toggle="yes">GABA toolkit</italic>
                    </td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LCModel GABA/GM</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.67 (0.88)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.66 (1.01)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.69 (0.77)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.932</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.59 (0.74)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.07 (0.75)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.23 (0.53)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LCModel SD (%)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.39 (2.30)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.47 (1.58)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.31 (2.83)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.843</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.50 (2.68)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.89 (0.78)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.00 (3.55)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LCModel SNR</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.00 (2.58)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.70 (2.26)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.37 (2.75)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.123</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.05 (2.42)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.44 (2.13)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.73 (2.69)</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LCModel FWHM</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08 (0.04)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06 (0.02)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09 (0.05)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.025 *</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07 (0.03)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06 (0.02)</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08 (0.04)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>* Significance values derived from independent sample <italic toggle="yes">t</italic>-tests or Chi Square tests where appropriate and significant, where <italic toggle="yes">p</italic> &lt; 0.05; <sup>a</sup> Hamilton Anxiety Rating Scale; <sup>b</sup> Montgomery–Asberg Scale of Depression; AGO—Agoraphobia; MDD—Major depressive disorder; PD—panic disorder; PTSD—Post-traumatic stress disorder; SAD—social anxiety disorder; SD—standard drink/10 g of alcohol; CSF—cerebrospinal fluid; df—degrees of freedom; dACC—dorsal anterior cingulate cortex; GM—grey matter; Fit Err—Fit error %; FWHM—full width at half-maximum; GABA—gamma amino-butyric acid; ROI—Region of interest, SNR—signal–noise ratio; SD—standard deviation; Tmt—treatment (group difference); WM—White Matter.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="nutrients-15-04586-t002">
              <object-id pub-id-type="pii">nutrients-15-04586-t002_Table 2</object-id>
              <label>Table 2</label>
              <caption>
                <p>Corrected GABA concentration changes, baseline to eight weeks.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GABA Model</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">B/Estimate</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">95% CI</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">t</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">df</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corrected GABA concentration</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" rowspan="1" colspan="1">Time</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.48</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">−0.09, 1.06</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">1.74</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">21</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.097 <sup>a</sup></td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" rowspan="1" colspan="1">Treatment</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">1.06</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.28, 1.83</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">2.75</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">46</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0 0.008 *</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" rowspan="1" colspan="1">Sex</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">−0.28</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">−0.78, 0.23</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">−1.14</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">21</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0 0.268</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" rowspan="1" colspan="1">Age</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.01</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.00, 0.03</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">1.58</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">19</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.129</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" rowspan="1" colspan="1">Comorbid</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.13</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">−0.39, 0.65</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.53</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">24</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.603</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" rowspan="1" colspan="1">Baseline alcohol </td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.05</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">−0.04, 0.03</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">1.58</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">21</td>
                    <td align="center" valign="middle" rowspan="1" colspan="1">0.129</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time*Treatment </td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.87</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−1.74, 0.00</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−2.09</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 0.049 *</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>* Significant at <italic toggle="yes">p</italic> &lt; 0.05; <sup>a</sup> Marginally significant at <italic toggle="yes">p</italic> = 0.05–0.10; B/coefficient unit decimal places are variable due to LCModel level ranges; df—degrees of freedom. </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
